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Abstract 
 
Objectives: The purpose of this Doctorate in Nursing Practice (DNP) project was to 
improve health outcomes among underserved residents of Nevada county by increasing access to 
inter-professional team-based medication assisted therapy (MAT) for opioid use disorder. The 
over-arching goal of this DNP project was to develop evidence based, interdisciplinary, nurse-
managed MAT services through the initiation of the pilot program for the newly developed MAT 
patient delivery system and the development of evidence-based nurse practitioner process 
protocols. 
Methods: This DNP project involved the coordination of an evidence-based, structured, 
nurse-managed MAT group on Wednesdays at Community Recovery Resources (CoRR) Grass 
Valley. The group was led by an interdisciplinary team and was attended by patients who were 
on a stable dose of an opioid agonist medication. The patients were required to attend the newly 
structured Wednesday group to obtain their Suboxone medication refill and any clinical concerns 
that the patient had or issues with their current maintenance therapy dose could be addressed by 
the provider at that time. Education regarding opioid use disorder, the use of Suboxone in the 
treatment of opioid use disorder as well as common side effects of the medication was provided 
during the group. The DNP author also assisted with the development of evidence-based nurse 
practitioner process protocols for the clinic site.  
Results: The retention rate for the patients in the newly developed MAT patient delivery 
system exceeded the established benchmark goal of 60%. The initial results of the patient 
satisfaction surveys regarding the MAT program were overwhelmingly positive. In addition, to 
accommodate the increased number of MAT patients who expressed interest in the new group 
format, an additional MAT group day was added on Tuesdays with plans to expand the group 
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format to additional CoRR campuses. The results of the provider satisfaction surveys regarding 
the MAT program will be added once all results are received.  
Conclusion: Medication-assisted treatment (MAT) has proven to be the most effective 
evidence-based treatment option for patients with opioid dependence combined with 
psychosocial treatment. Treatment of opioid misuse disorder with buprenorphine and naloxone 
and/or buprenorphine has been proven to be safe and an effective treatment option in the office-
based setting to decrease opioid use and cravings. Due to the new and evolving nature of the 
field of substance abuse and medication assisted treatment, it would be beneficial to obtain 
further research regarding best practices for providing MAT services to underserved non-
metropolitan communities.  
Keywords: medication-assisted treatment, opioids, substance use disorder, drug abuse, 
heroin, overdose deaths, opioid addiction, buprenorphine, opioid related disorders, rural, 
primary health care, mortality, and safety net. 
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Section I: Introduction 
Background Knowledge 
The American Society of Addiction Medicine (2016) characterizes addiction as a 
“primary, chronic and relapsing brain disease characterized by an individual pathologically 
pursuing reward and/or relief by substance use and other behaviors.” Opioids are a class of drugs 
that communicates with opioid receptors on nerve cells in the brain and the nervous system 
which results in feelings of pleasure and pain relief (American Society of Addiction Medicine, 
2016). This category of drugs includes prescription pain relievers such as oxycodone, 
hydrocodone, codeine, morphine and fentanyl and the illicit drug heroin. The Centers for Disease 
Control and Prevention (2017) reported that 42,000 Americans died from Opiates in 2016 which 
surpassed any other year on record. This number includes death from prescription opioids, heroin 
and fentanyl (Centers for Disease Control and Prevention, 2017).  According to the California 
Healthcare Foundation (2016), California ranks 37th for prescription opioid deaths although rural 
northern California counties had some of the highest overdose death rates in the country and 
limited access to addiction treatment. The development of Medication Assisted Therapy 
Services, frequently referred to as MAT services, was initiated in response to the significant 
increase in heroin and opioid-related overdoses in the United States and the adverse health 
outcomes associated with opioid addiction (SAMHSA-HRSA Center for Integrated Health 
Solutions, 2014). According to the SAMHSA-HRSA Center for Integrated Health Solutions 
(2014), there is increased access to MAT services in many states through the development and 
reform of Medicaid for those with substance use disorders, although, many do not receive these 
services do to underutilization or restricted access to these programs. The data indicates a 
significant need for nurse-managed community-based MAT services, especially in non-
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metropolitan Northern California counties, where opioid overdose rates remain high and access 
to services limited. Community Recovery Resources (CoRR) Grass Valley is a non-profit 
organization located in the Sierra Nevada foothills serving those with drug and alcohol addiction 
and related mental health disorders making it an ideal location for the implementation of nurse-
managed community-based MAT services, especially since its location is in a high risk non-
metropolitan Northern California county (Community Recovery Resources, 2018).  
Problem Description 
The opioid epidemic in America traces its roots back to the Civil War where opioids 
we’re being prescribed for pain, various illnesses and stress (Center for Substance Abuse 
Treatment, 2005). As the years passed the demographics of those addicted to opioids shifted to 
middle- and upper-class white women who were prescribed these medications for “female 
troubles” and Civil War veterans who were given opioids for medical procedures (Center for 
Substance Abuse Treatment, 2005). Although, physicians became less inclined to prescribe 
opioids by the close of the 19th century, and in turn, the amount of Americans addicted to 
opioids declined. In addition, social attitudes toward opioid addiction shifted from that of 
compassion and empathy to a society that viewed it as unethical and something that was frowned 
upon (Center for Substance Abuse Treatment, 2005).  
The opioid epidemic continues to be a significant medical and social issue in the United 
States today with the amount of overdoses due to opioids rising. The Centers for Disease Control 
and Prevention (2017) reported that 42,000 Americans died from Opioids in 2016 which 
surpassed any other year on record. This number includes death from prescription opioids, heroin 
and fentanyl (Centers for Disease Control and Prevention, 2017). Alarmingly, in the United 
States, drug overdoses are the leading cause of injury death and the rate of drug overdose deaths 
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is increasing in non-metropolitan areas compared to urban areas (Centers for Disease Control, 
2018). Mack, Jones and Ballesteros (2017) found in their report that the prevalence of drug use 
in non-metropolitan areas was lower than that of their urban counterparts but the ramifications of 
drug use in rural areas was increased (i.e. diagnosed with Hepatitis C virus or HIV). In addition, 
the authors stated that availability and access to substance abuse treatment services was less 
prevalent in non-metropolitan communities (Mack, Jones, & Ballesteros, 2017). Noonan (2017) 
details the disparities that non-metropolitan communities face such as socio-economic factors, 
health practices and access to health care services which makes these communities vulnerable to 
the opioid epidemic. 
Although the total opioid related death rates in California are lower than the numbers in 
other states, there remains specific counties in California that have some of the highest opioid 
prescribing rates and death rates in the United States (Joshi & Urada, 2017). Rural Northern 
California counties have the leading number of opioid prescriptions per 1,000 residents and 
prescription opioid related deaths per resident is also highest in these same counties (Joshi & 
Urada, 2017). Furthermore, Joshi and Urada (2017) state that while Nevada, El Dorado, Colusa, 
Mendocino, Del Norte and Humboldt counties have some of the highest overdose death rates, 
fewer than 10 patients were enrolled in opioid treatment programs in 2016. In addition, in 2016, 
the top eight counties in Northern and Central Eastern California with the highest number of 
opioid overdoses did not have Narcotic Treatment Programs (NTP) (Joshi & Urada, 2017). The 
data highlights a significant need for treatment options for this patient population specifically in 
non-metropolitan Northern California counties who remain the hardest hit by the opioid 
epidemic in California. 
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In response to the opioid epidemic in California, the state developed a California Hub and 
Spoke System (H&SS) included in the MAT Expansion Opioid State Targeted Response (STR) 
grant program which is based on the Vermont Hub and Spoke Model (Darfler et al., 2018). The 
Vermont Hub and Spoke Model is based on developing a structured specialty and referral 
network for both higher levels of care and office-based treatment environments (Darfler et al., 
2018). The California Hub and Spoke MAT Expansion Program was created to “improve, 
expand, and increase access to MAT services throughout the state, especially in counties with the 
highest overdose rates” (Darfler et al., 2018). The goal of this program is to increase the number 
of providers (i.e. physicians, nurse practitioners, physician assistants) who are prescribing 
buprenorphine for opioid misuse disorder which in turn would make MAT more accessible for 
this patient population in the highest risk regions of the state (Darfler et al., 2018).  
MAT in conjunction with psychosocial treatment has been shown to be the most effective 
evidenced based treatment option for this patient population (Jones, 2018). There are several 
medication options for MAT, but this paper and DNP project focused on Buprenorphine. 
Buprenorphine is an opioid agonist/antagonist that obstructs the effects of other narcotics while 
at the same time reducing the withdrawal risk and has several different formulation options 
(Center for Substance Abuse Treatment, 2016). An advantage of Buprenorphine in comparison 
to Methadone treatment for opioid dependency is that Buprenorphine is the first medication that 
is authorized to be prescribed and given in a healthcare provider’s office instead of a highly 
structured clinic increasing patient access to treatment (Center for Substance Abuse Treatment, 
2016). Although, the use of this medication is not intended to be in isolation and is most 
effective in combination with counseling and behavioral therapy representing a comprehensive 
“whole-patient approach” (Center for Substance Abuse Treatment, 2016). Physicians are 
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mandated to attend an 8-hour training session to be granted a Drug Enforcement Agency (DEA) 
waiver to have prescribing ability of Buprenorphine and prescribing ability for other health care 
providers is broadening (Jones, 2018).  
The location of Community Recovery Resources (CoRR) Grass Valley in a non-
metropolitan Northern California county made it an ideal location to serve a community at high 
risk for prescription and illicit opioid dependence and opioid related death. As previously 
discussed, the research indicates that non-metropolitan communities have high rates of 
prescription and illicit opioid use and related deaths and decreased access to medication assisted 
therapy. In addition, according to the Community Recovery Resources (CoRR) Chief Executive 
Officer (CEO), approximately 75% of people receiving services at CoRR are low income 
(Curtis, 2018). This presented an opportunity to better serve this high-risk community through 
the development and implementation of a nurse managed community-based medication assisted 
therapy services, through the support of the California H&SS grant, to address and combat the 
effects of the opioid epidemic in this area and support continued sobriety and health and well-
being in this patient population.  
Specific Aims 
The over-arching aim of this DNP project was to improve health outcomes among 
underserved residents of Nevada county by increasing access to inter-professional team-based 
MAT for opioid use disorder through the development of evidence based, interdisciplinary, 
nurse-managed MAT services through the initiation of the pilot program for the newly developed 
MAT patient delivery system and the development of evidence-based nurse practitioner process 
protocols. An aim statement was created to address the proposed programs intended 
improvement to practice and is as follows, by March 2019, Community Recovery Resources 
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(CoRR) Grass Valley Campus will develop and implement nurse-managed community-based 
medication assisted treatment services in Nevada county to improve access and health outcomes 
for those with opioid use disorder with a retention rate benchmark goal of 60% for patients in the 
program. In addition, based on the success of this DNP project, an aim is to expand the nurse 
managed-community based medication assisted treatment services to be offered on additional 
days at the CoRR Grass Valley campus as well as to additional campus locations.  
PICOT 
 The PICOT question developed for the aforementioned DNP project is as follows: In 
patients with opioid use disorder in an underserved non-metropolitan Northern California 
community, will increasing access to interprofessional team-based MAT for opioid use disorder 
improve health outcomes? 
Search Process 
A review of the literature was conducted to examine the lack of access to MAT for 
underserved residents in non-metropolitan communities with opioid misuse disorder. In addition, 
a literature search was conducted to determine the current demographic landscape of illicit and 
prescription opioid dependent users and the economic impact of prescription opioid overdoses, 
abuse and dependence. Although there are several options for maintenance therapy for opioid 
dependence, the focus of this DNP project and research was specifically on office-based use of 
buprenorphine-naloxone. Lastly, the research conducted also evaluates the decreased risk of 
other comorbidities, such as Hepatitis C, in opioid dependent patients who receive opioid agonist 
therapy. The key words used in the search process were: medication-assisted treatment, opioids, 
substance use disorder, drug abuse, heroin, overdose deaths, opioid addiction, buprenorphine, 
opioid related disorders, rural, primary health care, mortality, and safety net. The databases 
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utilized in the search were the Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), PubMed, Google Scholar and Cochrane. The search was conducted in September-
November of 2018 and generated 107 articles. The inclusion criteria for articles that were 
selected were articles published between the years of 2001-2018, those written in English, those 
examining illicit and prescription opioid use, medication assisted therapy for opioid 
abuse/dependence, demographic characteristics of opioid misuse and the economic impact of 
opioid overdose, abuse and dependence. The exclusion criteria included articles not written in 
English and those published before 2001.  
Evidence Appraisal Tool  
 The research articles selected for this DNP project were appraised utilizing the John 
Hopkins Evidence-Based Practice (JHNEBP) Research Evidence Appraisal Tool (Appendix R). 
This rating scale examines the strength of the evidence (i.e. Level I-V) and the quality of the 
evidence (i.e. A-C).  
Review of the Evidence 
The opioid epidemic remains at the forefront as a significant medical and social issue in 
the United States today. Although California as a state has lower opioid related death rates when 
compared to the numbers in other states, specific counties in California continue to have some of 
the highest opioid prescribing rates and death rates in the United States (Joshi & Urada, 2017). 
As previously mentioned, Joshi and Urada (2017) further state that specifically counties in rural 
Northern California counties have some of the highest prescription opioid prescribing rates and 
prescription opioid related death rates in the country. Cicero et al. (2014) describes the 
demographic shift in Heroin users, many previously prescription opioid dependent, from 
minority inner city users to Caucasian men and women living in non-metropolitan areas. 
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Although the data has demonstrated a significant amount of opioid misuse and dependence in 
non-metropolitan areas, Rosenblatt et al. (2015) report that only 3% of primary care providers 
had received the Drug Enforcement Administration (DEA) DATA waivers which represents the 
biggest group of providers in non-metropolitan areas in the U.S, indicating a lack of access to 
office-based treatment for opioid disorders in rural areas. In addition, Jones (2018) state that 
health care centers located in non-metropolitan areas were less likely to provide on-site 
buprenorphine treatment.  
Jones (2018) reports that the most effective evidence-based treatment option for patients 
with opioid dependence is MAT in conjunction with psychosocial treatment. Furthermore, 
research conducted by Renner et al. (2003) concluded that treatment with combination 
buprenorphine and naloxone and buprenorphine were safe for use and a reduction in the use of 
opiates and cravings were seen for patients that were opiate dependent and receiving these opioid 
agonist medications in the office-based setting. In addition, a study conducted by Tsui et al. 
(2014) found that the use of opioid agonist therapy, either methadone or buprenorphine, may 
help to prevent the contraction of hepatitis c infection in this patient population. Increased access 
to opioid agonist treatment (i.e. methadone or buprenorphine) can also be correlated with a 
reduction in the number of heroin overdose deaths (Schwartz, 2013).  
Theoretical Framework 
Treatment of the opioid dependent patient is multi-faceted and dynamic and applying an 
ecological model for health promotion in this patient population addresses both individual and 
social environmental factors allowing for more comprehensive interventions and treatment 
modalities (McLeroy, Bibeau, Steckler & Glanz, 1988).  
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The ecological perspective is centered on the idea that behavior is affected by “multiple 
levels of influence” and that an individual’s behavior both affects and is affected by the social 
environment (U.S. Department of Health and Human Services, National Cancer Institute, 2005). 
This framework focuses on the interaction of and the interconnection between the different levels 
of influence of a health problem (U.S. Department of Health and Human Services, National 
Cancer Institute, 2005). McLeroy, Bibeau, Steckler and Glanz (1988) define five levels of 
influence when looking at health related behaviors and conditions which consist of 1) 
intrapersonal or individual factors; 2) interpersonal factors; 3) institutional or organizational 
factors; 4) community factors; and 5) public policy factors (U.S. Department of Health and 
Human Services, National Cancer Institute, 2005). Through targeted interventions at all levels of 
influence a patient’s unhealthy behavior(s) can be changed and modifying the social environment 
can lead to behavior changes in the individual as well (McLeroy, Bibeau, Steckler & Glanz, 
1988).  
Providers can target interventions at the intrapersonal level by focusing on the patient’s 
distinct characteristics that impact their behavior (U.S. Department of Health and Human 
Services, National Cancer Institute, 2005). Interventions at the intrapersonal level for the opioid 
dependent patient would include screening measures to prevent further adverse outcomes and 
educational programs directed at opioid misuse. Based upon findings of screening measures 
employed, the provider can institute interventions to treat the opioid dependency such as MAT,  
counseling, support groups etc. Interventions at the inter-personal level would consist of peer 
support groups (i.e. Narcotics Anonymous, MAT groups), family support groups, group therapy 
and residential or transitional living support groups. The community level of influence includes 
institutional and community factors as well as public policy (U.S. Department of Health and 
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Human Services, National Cancer Institute, 2005). Efforts at the institutional level, when 
examining opioid dependence, focus on adhering to trusted guidelines for prescribing opioids 
(Centers for Disease Control and Prevention, 2017) and abiding by state prescription drug 
monitoring policies (i.e. Cures). Examples of community factors would include social media 
opioid misuse awareness campaigns and the distribution of Narcan kits to the community. Lastly, 
an example of interventions directed at the public policy level would include legislation focused 
on increasing access to medication-assisted therapy for opioid dependent patients in high risk 
non-metropolitan communities.  
This DNP project employed the ecological framework when examining the opioid 
epidemic and in the development of interventions for the patient with opioid use disorder as this 
perspective applies a multilevel approach to a health problem and incorporates the role of the 
social environment. Utilizing the ecological framework as a guide for the DNP project 
intervention allowed for the provision of comprehensive, interdisciplinary care for the patient 
with opioid use disorder.  
Section II: Methods 
Setting 
 The DNP project implementation site is CoRR in Grass Valley and it is a non-profit 
organization that has been serving the community since 1974 through substance abuse treatment 
programs and providing mental health services since 2002 (Community Recovery Resources, 
2018). CoRR Grass Valley is located in the Sierra Nevada foothills and offers extensive 
substance abuse treatment and primary care treatment. The mission of CoRR is to “support the 
communities [they] serve with a full spectrum of wellness-focused programs to reduce the social, 
health and economic impact on families and children from all types of substance abuse and 
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behavioral health issues” (Community Recovery Resources, 2018). The organization focuses on 
a “whole-person approach in treating substance abuse, related addictions and associated 
behavioral issues” and has five other campuses in the region (Community Recovery Resources, 
2018).  
The clinic serves a non-metropolitan high risk opioid dependent population that are either 
being treated as an outpatient, in residential treatment or are in transitional living. Nevada county 
is a non-metropolitan county that is located between Sacramento and Tahoe. It has a population 
of approximately 99, 814 and is predominantly Caucasian (85.2%) (U.S. Census Bureau, 2017). 
The median household income is $57,429 which falls below the median income for California 
($63,783) (U.S. Census Bureau, 2017). CoRR has been identified as the primary nonprofit 
provider of substance use disorder and related behavioral services for Nevada and Placer 
counties in California. In Nevada county it is estimated that there are 230-594 patient with opioid 
use disorder that do not have local access to MAT (Clemens-Cope, Epstein, & Wissoker, 2018).  
Furthermore, in Placer county it is estimated that 686-2,149 patients with opioid use disorder 
who do not have local access to MAT (Clemens-Cope, Epstein, & Wissoker, 2018).   
The treatment team consists of a physician, nurse practitioner, physician assistant, 
program coordinator and two medical assistants. CoRR Grass Valley received a California Hub 
and Spoke (H&SS) System Grant to improve and expand access to medication-assisted therapy 
for opioid dependent patients (Appendix D, E). The clinic was in the initial stages of utilizing the 
grant funds for medication-assisted treatment and did not have approved process protocols, 
updated prescribing policies for buprenorphine and naltrexone or updated MAT treatment forms 
at the initiation of the DNP project.  
Context 
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 The DNP project was implemented in a community-based setting at a substance use 
recovery clinic in a non-metropolitan county in northern California. The identified patient 
population were underserved residents of a non-metropolitan community who had opioid use 
disorder.  
 Prior to the implementation of the project, the DNP student collaborated with the Medical 
Director, Nurse Practitioner, Physician’s Assistant, Clinical Coordinator and the Substance Abuse 
Counselor to develop a nurse managed, interdisciplinary, evidence-based structured clinical 
schedule, protocol and workflow for the MAT group patients on Wednesdays (Appendix K, M) 
and discuss the logistics of the project. There were 47 patients with opioid use disorder, who were 
on a stable maintenance dose of Suboxone, who participated in the MAT Wednesday pilot 
program. The MAT Wednesday group was led by the Substance Abuse Counselor, in collaboration 
with the Medical Director, Nurse Practitioner, Clinical Coordinator DNP student and Medical 
Assistant for approximately one hours in conference room #104 at the CoRR Grass Valley campus. 
The Medical Director, Nurse Practitioner and DNP student were available to answer any questions 
the patients may have during the group and to see patients after group who had a clinical concern 
or needed an adjustment of their maintenance Suboxone dose. A comprehensive description of the 
interventions of this DNP project can be found in the interventions section of this paper.  
Key Stakeholders 
The primary stakeholders of this DNP project were the patients and families served and 
the Nevada and Placer communities. Feedback from the primary stakeholders regarding the 
newly developed MAT group was received through the use of anonymous patient satisfaction 
surveys administered in February 2019 and again in April 2019 for continuous evaluation of the 
strengths and weaknesses of the program. The organizational stakeholders were Ariel King 
THE DEVELOPMENT AND IMPLEMENTATION OF  19 
 
Lovett (Chief Executive Officer), Dr. Scott Kellerman (Medical Director, project oversight), Dr. 
Alexa Curtis, PhD, MPH, FNP-BC (project coordinator), Michelle Otten (Clinical Coordinator), 
and Lauren Knapp, DNP student intern as the project manager. The organizational stakeholders 
were involved in the development and revision of the MAT group pilot program through 
interdisciplinary weekly meetings prior to the start of the group and through email. The 
implementation of nurse managed community-based medication assisted treatment services for 
an underserved non-metropolitan northern California community at CoRR Grass Valley was 
sanctioned by the CoRR Medical Director, Dr. Scott Kellerman, the CoRR Nurse Practitioner, 
Dr. Alexa Curtis, and the CoRR Clinical Coordinator Michelle Otten. The aforementioned 
project proposal was approved by committee chair Dr. Alexa Curtis. A written letter of support 
from Community Recovery Resources (CoRR) is included (Appendix B). Lastly, prior to the 
implementation of the DNP project a memorandum of agreement (MOU) was signed between 
the University of San Francisco (USF) and the project site, Community Recovery Resources 
(CoRR) in Grass Valley.  
Communication Flow 
The fluid communication flow between all members of the interdisciplinary team was 
imperative for the success of the DNP project. The DNP student was in direct communication 
with the Committee Chair and members of the collaborative treatment team at CoRR Grass 
Valley throughout all stages of the project.  Any revisions to the format of the MAT group, 
updated clinical documentation or change in the process or protocols was communicated to all 
members of the team. A detailed communication plan was created for the DNP project 
(Appendix H). 
GANTT Chart  
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A GANTT chart was created to organize each step of the DNP project and highlight the 
projected milestones (see Appendix J). Prior to the initiation of the project, a literature review 
was conducted regarding opioid dependence and medication assisted therapy for opioid 
dependence. After the DNP clinical improvement project topic was approved, the DNP student 
then created a project team. Meetings with the DNP student and the stakeholders and members of 
the health care team at the project implementation site were conducted. The DNP student, in 
collaboration with the Clinical Coordinator and Substance Abuse Counselor, identified patients 
to be enrolled in the structured MAT Wednesday clinic groups. The development of MAT group 
policies and workflows, updated prescribing policies, process protocols and patient and provider 
resources were developed at this time. The DNP project implementation occurred over a four-
month period beginning in January to April 2019 after which data was collected analyzed. A 
Patient satisfaction survey was disseminated in February of 2019, one month after the initiation 
of the project implementation, and again in April of 2019 to receive feedback from the MAT 
patients regarding the program and to allow for any revisions to be made to the format of the 
group. A provider satisfaction survey was also conducted in the month of April 2019. Lastly, the 
final DNP written project began in April 2019 and the presentation of the project and results 
were presented to the USF faculty in May 2019.  
Gap Analysis  
The purpose of a gap analysis is to improve processes through examining the current state 
of the issue being addressed, determine the future goal of where one would like that state to be, 
and create a plan of how to achieve that desired state. A gap analysis was conducted for the 
proposed DNP project (Appendix I). A study conducted by Jones (2018) found that health 
centers in non-metropolitan areas were less likely to provide on-site buprenorphine treatment and 
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had decreased odds of having an interest in expanding services to provide buprenorphine 
treatment. Furthermore, research conducted by Rosenblatt, Andrilla, Catlin, and Larson (2015) 
concluded that most counties in the United States did not have access to waivered physicians to 
prescribe buprenorphine-naloxone and suggested increasing access to office-based opioid 
dependence treatment especially in rural areas where access to such services was limited. 
Currently, as evidenced by the data, there is limited access to MAT services in non-metropolitan 
areas where opioid prescription rates and prescription opioid related deaths remain high. It is 
essential that in the future there is increased access to community-based medication assisted 
therapy for opioid dependence for this high-risk population to counteract the ravaging effects of 
the opioid epidemic on high risk communities. Community Recovery Resources located in Grass 
Valley is located in Nevada county, a non-metropolitan community in Northern California that 
has a high risk opioid dependent population making it an ideal site for practice improvement.  
SWOT Analysis 
A SWOT analysis was conducted to identify the strengths, weaknesses, opportunities and 
threats that could affect the implementation of the nurse-managed community-based medication 
assisted treatment services for the underserved community of Nevada county (see Appendix C).  
A valuable strength of this project is that it addressed the issue of inadequate access to MAT 
services for opioid dependent patients in non-metropolitan areas, especially in rural Northern 
California counties where opioid prescription rates and opioid related death rates are highest. 
Additional strengths of this project were the potential impact it could have on the rate of 
prescription opioid related deaths and decreased rates of transmission of communicable diseases 
such as Hepatitis C. Furthermore, the DNP project could result in a potential cost savings 
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through the decreased utilization of inpatient detoxification services and the increased 
distribution of Narcan kits to the community and high-risk groups.  
A weakness of the project is the lack of waivered prescribers to meet the treatment needs 
of the MAT patients. In addition, other weaknesses are the lack of patient transportation to CoRR 
Grass Valley for treatment and patient demographics such as unstable housing, geographical 
distance from the clinic and lack of support system. Lastly, other weaknesses are patients not 
being covered by the H&S grant and those who are unable to pay for treatment and patient 
adherence to Suboxone induction/maintenance therapy.  
The DNP project offers an invaluable opportunity to serve the community of Nevada 
county and those patients that belong to vulnerable, high risk groups. This project provides the 
opportunity to increase access to MAT services to this non-metropolitan community and reduce 
the number of illicit and prescription related deaths. There is also an opportunity for continued 
H&S grant funding for the MAT program at CoRR. An additional opportunity that this project 
presents is to reduce the transmission of communicable diseases in this high-risk population 
through the use of opioid agonist medication adherence and education. Lastly, there is an 
opportunity to provide education to patients, families and the community regarding the use of 
Narcan and its lifesaving properties and also dispense physical Narcan kits.  
The SWOT analysis conducted identified the following potential threats to the project: 
loss of H&SS funding, opioid dependent patients in need of MAT services unable to access 
treatment, pharmacies out of stock of opioid agonist medication, patients leave MAT treatment, 
no change in the rate of illicit and prescription opioid related deaths and a loss of waivered 
prescribers.  
Budget  
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  The medication-assisted treatment services at CoRR Grass Valley is funded through the 
California Hub and Spoke (H&SS) Grant (Appendix D, E). The clinic is directly reimbursed for 
the salary and benefits of one FTE Nurse and one FTE Clinician/Counselor per 100 H&S 
patients (i.e. 0-20 patients = 8 hrs. paid per week, 20-40= 16 hrs. paid per week, etc.).  For 
Physicians and Mid-Level waivered providers the H&S grant reimburses $180 for Suboxone 
induction office visits for uninsured and underinsured patients and $100 for Suboxone follow-up 
visits. The grant also reimburses for patient transportation, physician and mid-level time in 
training and MAT training materials. The Clinical Coordinator submits a monthly invoice form 
to Aegis for reimbursement, whom the H&S grant is funded through, and reports the monthly 
personnel costs (i.e. MAT Nurse, MAT clinician), Provider H&S induction and follow-up, 
treatment services (drug testing, human immunodeficiency virus (HIV) and Hep-C testing, 
Suboxone/Naloxone/Vivitrol costs, miscellaneous services (i.e. bus passes, gas/fuel cards, 
trainings, infrastructure) and outreach and advertising expenses (Appendix D, E).  
  The clinic personnel, providers, treatment services and miscellaneous services are 
reimbursed through the H&SS Grant and were therefore not included in the DNP project budget. 
A budget for the development and implementation of this DNP project was created and included 
direct and indirect costs (Appendix F).  Direct costs incurred for the project were for materials, 
coffee and donuts on the first day of the MAT Wednesday group and NP travel costs (i.e. 
mileage/gas). The cost of materials totaled $65.78 and included patient satisfaction surveys, 
handouts, and writing utensils to fill out the surveys. On the first day of the MAT Wednesday 
pilot program coffee and donuts were provided for the patients that attended as well as the 
interdisciplinary team and the cost totaled $50. Lastly, the DNP student traveled by car to the 
clinic site in Grass Valley which is approximately 98 miles a week, for at least two Wednesdays 
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a month, for four months totaling $240 in fuel cost. The total cost of direct expenses was 
approximately $356 paid out-of-pocket by the DNP student. The indirect expenses accounted for 
the DNP student’s time and project management and implementation and totaled $3,904. The 
total budget, including both direct and indirect expenses was $4,260.  
  Florence, Luo, Xu and Zhou (2016) report that prescription opioids are responsible for 
70% of fatal prescription drug overdoses and the number of overdose deaths due to prescription 
drugs is considered to be an epidemic. It is imperative that the economic impact of prescription 
opioid overdose, abuse and dependence in the United States be understood as this data will 
influence future clinical practice in treating this patient population, future research and 
legislation (Florence, Luo, Xu and Zhou, 2016). Florence, Luo, Xu and Zhou (2016) examined 
the societal costs of prescription opioid abuse, dependence and fatal overdose in the United 
States based on the most up to date applicable data for the calendar year 2013 (Appendix F). The 
authors further differentiated between nonfatal costs such as health care, substance abuse 
treatment, criminal justice and lost productivity and fatal costs defined as lost productivity and 
health care (Appendix F) (Florence, Luo, Xu and Zhou, 2016). Florence, Luo, Xu and Zhou 
(2016) estimate that the total economic cost of prescription opioid overdose, abuse and 
dependence is $78.5 billion. Furthermore, they report that $28.9 billion is spent on increased 
health care costs and substance abuse treatment expenses which accounts for over one third of 
the total economic cost (Florence, Luo, Xu and Zhou, 2016). Lastly, the authors report that the 
public sector absorbs roughly one quarter of the estimated total economic cost through 
expenditures related to health care, substance abuse treatment and criminal justice (Florence, 
Luo, Xu and Zhou, 2016). 
  When examining the cost benefit of this project, the total nonfatal cost of prescription 
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opioid misuse in the United States in 2015 was examined based on data from Florence et al. 
(2016) (Council of Economic Advisors, 2017). The nonfatal costs include increased healthcare 
and substance abuse treatment costs ($29.4 billion), increased criminal justice costs ($7.8 billion) 
and reduced productivity among those who did not die of overdose ($20.8 billion) (Council of 
Economic Advisors, 2017). It is to be noted that this data includes the average cost estimates for 
prescription opioid disorders only (Council of Economic Advisors, 2017). The estimated cost to 
implement the DNP project for a full year was $12,779. The benefit of implementing the DNP 
project over the course of year would be increased access to evidence based, interdisciplinary 
MAT services for high-risk, underserved patients with opioid use disorder in non-metropolitan 
communities and in turn decrease the increased healthcare costs, criminal justice costs and 
decreased productivity associated with the diagnosis.  The calculated cost benefit ratio of the 
DNP project was 2.35 which indicates that it is “economically satisfactory” (Tayari, 2018).  
Interventions  
Developmental Phase: During the initial phase of this project research was conducted on 
the opioid epidemic in the United States, the current demographics of this epidemic, the 
economic burden of opioid dependency, abuse and overdose and best practices for medication-
assisted therapy for opioid dependence and the California Hub & Spoke Grant for MAT services 
to address the epidemic. The project manager then proposed the clinical improvement project to 
the Medical Director, Nurse Practitioner, Physician’s Assistant and Clinical Coordinator at 
CoRR Grass Valley. During this phase the project manager sought educational opportunities to 
become more knowledgeable about medication-assisted treatment for opioid addiction in opioid 
treatment programs through reading the Substance Abuse and Mental Health Services 
Administration (SAMHSA) “Treatment Improvement Protocol TIP 43”, discussing opioid 
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dependency and MAT practices with CoRR providers and local experts (i.e. Grace Katie Bell, 
MSN, RN-BC CARN PHN at Chapa De Indian Health), shadowing an experienced MAT 
provider at El Dorado Community Health Center and reviewing California’s Hub and Spoke 
System Learning Collaborative power point. The project manager also participated in 
Wednesday morning staff meetings with the Medical Director, Nurse Practitioner, Physician’s 
Assistant and Clinical Coordinator discussing the development of the MAT program at CoRR, 
complex patient cases and any current clinical issues.  
 During this phase, the DNP student met with the Clinical Coordinator and Substance 
Abuse Counselor to determine which patients would be appropriate to participate in Wednesday 
MAT group classes with the interdisciplinary team, at which time, Suboxone medication refills 
for maintenance therapy would be dispensed and any patient clinical concerns or medication 
dosing concerns would be addressed. The DNP student met with her Committee Chair, Dr. Alexa 
Curtis, and presented the DNP project proposal which was approved for implementation. A 
memorandum of agreement (MOU) was obtained between the University of San Francisco and 
the project implementation site, CoRR Grass Valley prior to implementation.  
Educational and Delivery of Interventions into Practice Phase: The DNP student led 
the coordination of the MAT Wednesday group classes with the interdisciplinary team including 
securing the conference room for the group, communicating with all members of the team, 
assisting in notifying patients of acceptance into MAT Wednesday group class and opioid 
agonist medication refill schedule (i.e. attendance at Wednesday class mandatory for medication 
refill, any clinical concerns can be addressed at Wednesday group class) (Appendix K).  
The Wednesday MAT group class was held by Steve Black, Substance Abuse Counselor 
at CoRR Grass Valley, and all MAT providers were present during the MAT group. The 
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interdisciplinary team of MAT providers present at the group included the Medical Director, 
Nurse Practitioner, Clinical Coordinator, DNP student and Medical Assistant(s). The structure of 
the Wednesday MAT group to include the interdisciplinary team, and behavioral health therapies 
in conjunction with pharmaceutical management is aligned with best practice for the treatment of 
opioid use disorder (American Association of Addiction Medicine (ASAM), 2015). Prior to the 
start of the MAT group, each patient was expected to provide a urine sample for urine drug 
screen, in concordance with their contract for being on opioid agonist therapy (i.e. Suboxone), 
and they were to fill out the first page of the Suboxone maintenance therapy progress note 
(Appendix L). The progress note allowed the patient to communicate with the MAT provider 
their current maintenance dose of Suboxone, their refill schedule and preferred form of the 
medication (i.e. SL strips or tablets), how they were doing on their current maintenance dose, if 
they had used alcohol in the past week and if they had any clinical concerns or needed to be seen 
by a provider after the group.  
 The topics covered during the one-hour MAT group were based on subject matter 
developed by Kaiser Permanente for the standard medical management of opioid dependence 
with Suboxone in a group setting (Kaiser Permanente, 2015). There was on average, 12 patients 
present for each MAT group and each patient would do a “weekly check-in” at the start of each 
group. Each patient would introduce themselves to the group, state how many “sober days” they 
had thus far, discuss cravings experienced in the last week, benefits/side effects of 
buprenorphine/naloxone, what self-help meetings they had attended that week and any emotional 
or physical pain experienced and the coping skills they had utilized. Patients also were able to 
ask the MAT providers questions regarding Suboxone, side effects they were experiencing or 
any other clinical concerns in real time during the group and also had the opportunity to meet 
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with the MAT provider after the group in the clinic to have their concerns addressed. The DNP 
student, in collaboration with the Medical Director and Nurse Practitioner, also helped to screen 
and diagnose opioid use disorder for newly admitted patients and provided MAT services to new 
and established patients at CoRR.   
During this phase, the DNP student assisted in the development of new updated 
prescribing policies procedures (Appendix M) and a specific maintenance therapy progress note 
for the MAT group (Appendix K). The updated prescribing policies are awaiting final approval 
by the Medical Director at the time that this paper was written. In addition, modifications were 
made to the Wednesday MAT group structure and associated documentation based on patient 
and provider feedback throughout the course of the program. After the initial MAT groups in 
January, a need was identified for an updated MAT progress note for the groups as some of the 
documentation was not pertinent for patients attending the group or could not be obtained due to 
the nature of the group setting as well as other documentation that was needed that was not on 
the initial form.  Due to the positive feedback and interest after the initial MAT Wednesday 
groups in January, the program was expanded to include an additional MAT group on Tuesdays. 
A patient satisfaction survey was disseminated in March, two months after the start of the DNP 
project, to collect patient feedback on the newly implemented program (Appendix N) and allow 
for any changes to be made. The DNP project implementation occurred over a four-month period 
although, was extended into practice after the established completion date due to the success of 
the program with plans to expand to other CoRR locations.  
The interventions of this DNP project were guided by the ecological framework as opioid 
use disorder is multi-dimensional and the different levels of this perspective allow for 
comprehensive and collaborative treatment for patients with this disorder. The intrapersonal and 
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interpersonal levels of the ecological framework were addressed through the interventions 
through the MAT services provided to the patients and families. The institutional and 
organizational levels of the framework were fulfilled through the creation of updated policies, 
procedures and process protocols as well as updated MAT group maintenance therapy progress 
notes. Lastly, the community aspect of the ecological framework was addressed through the 
DNP student meeting with community experts on opioid use disorder and stakeholders.  
Method of Evaluation  
   During the educational and delivery phase of the project, a paper patient satisfaction 
survey was administered two months after the project implementation and at project completion 
to obtain quantitative data regarding MAT services utilizing a Likert scale. In addition, 
descriptive statistics were obtained in regard to patient age, gender and poverty level. Qualitative 
data was obtained through a narrative portion of the patient satisfaction survey and also through 
individual interviews with MAT patients and providers.  A provider satisfaction survey was 
obtained online through Survey Monkey at the completion of the project to gain feedback about 
the project. Lastly, retention in recovery will be analyzed through the use of MAT group 
attendance data and will be evaluated against the benchmark of 60% based on the literature 
(Lagisetty, Klasa, Bush, Heisler, Chopra, Bohnert, 2018).   
  The objectives of the DNP project were: 
1.  Increase access to nurse managed, inter-professional, team-based medication assisted 
therapy (MAT) for opioid use disorder through the attendance of at least 10 patients 
at the first Wednesday MAT group on January 2nd, 2019.  
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2. The creation of updated policies, procedures and process protocols based on 
evidence-based practice for Nurse Practitioners at CoRR, in collaboration with the 
other MAT team members, by April 24th, 2019.  
3. Measure the success of the newly developed MAT group delivery system in meeting 
the needs of the patient with opioid use disorder through the calculation of the 
retention in recovery rate and compare that against the benchmark of 60% in the 
literature by April 25th, 2019.  
Patient Satisfaction Survey. A paper patient satisfaction survey regarding the MAT 
Group program on Tuesdays and Wednesdays was given two months after the start of the 
program in March 2019, and at the project completion in April 2019 (Appendix N). The patient 
satisfaction survey questions were appropriated from a patient satisfaction survey created by Lee, 
Arria, Hsu and Wish (2003) for a pilot study that they conducted regarding patient satisfaction 
with drug treatment in Maryland.  The survey was anonymous and consisted of five questions 
with the last question allowing for a narrative response from the patient. The responses from the 
two groups of MAT patients were examined and an excel bar graph was created based on the 
responses from questions one through four. Patterns were identified from the patient responses to 
the last narrative question on the survey.  
 Provider Satisfaction Survey. An electronic, anonymous, provider satisfaction survey 
regarding the MAT Group program was created using Survey monkey and sent to the Medical 
Director, Nurse Practitioner and Clinical Coordinator at the completion of the DNP project. 
There were four questions created by the DNP student. The first three questions addressed what 
qualities or characteristics the provider felt made a successful MAT program, what qualities or 
characteristics they felt made a successful MAT program at CoRR and what they would like to 
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see changed or improved upon. The last question asked if they would like to see the Tuesday and 
Wednesday MAT Group continue at CoRR and allowed for a yes or no answer or “other” with a 
space provided for comments.  
Analysis  
The quantitative data obtained from the patient satisfaction surveys regarding satisfaction 
with MAT Group services, utilizing a Likert scale, was entered into an Excel spreadsheet and a 
bar graph was generated displaying the results of the survey. Descriptive statistics were collected 
regarding patient age, gender and poverty level/funding status and were displayed in a table. 
MAT Group attendance data was entered into an Excel spreadsheet, including demographic data 
such as gender and age range, and the retention rate in recovery was calculated into a percentage 
to compare with the benchmark of 60% established in the literature. A provider satisfaction 
survey was administered electronically, which yielded narrative responses to questions and was 
included in a table.   
Ethical Considerations 
The proposed DNP project was approved by the University of San Francisco School of 
Nursing and Health Professions as a quality improvement project exempt from institutional 
review board (IRB) (Appendix A). In addition, a memorandum of understand (MOU) was signed 
between the University of San Francisco and Community Recovery Resources (CoRR) prior to 
the project’s implementation. The project was in compliance with the Health Insurance 
Portability and Accountability Act (HIPAA) and any and all patient names and/or identifiers 
were excluded. The protection of participants physical and psychological well-being was of 
utmost importance throughout the entirety of this project. There were no conflicts of interest. 
When reflecting on the Jesuit values, the value of “men and women for and with others” and 
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“contemplative in action” (Regis University, 2018) was demonstrated in this clinical 
improvement project. The value of “men and women for and with others” is demonstrated 
through being of service and supporting the “poor and marginalized” (Regis University, 2018). 
The purpose of this project was to improve health outcomes and increase access to medication-
assisted therapy (MAT) to an underserved population with a goal of being of service and 
supporting those with opioid use disorder with evidenced based practices as this population are 
often marginalized by society. Furthermore, the value of “contemplative in action” can be seen in 
this project through the identification of a social problem and the creation of an action plan to 
address this issue.  
The first provision of the American Nurses Association (ANA) Code of ethics states that 
the “nurse practices with compassion and respect for the inherent dignity, worth and unique 
attributes of every person” (American Nurses Association, 2015). Throughout the course of this 
paper and project implementation, interventions and care have been provided with compassion 
and respect for the patient and their dignity and worth has been recognized and preserved.  
Section III: Results  
Patient Satisfaction Surveys. A five-question paper patient satisfaction survey was 
obtained one month after the implementation of the project in February 2019 to provide feedback 
regarding the MAT services provided on the Tuesday and Wednesday groups yielding 17 
respondents (Appendix O). The first question asked, “Would you rate the quality of service you 
have received on the Wednesday MAT group as “excellent”? Answer choices included “yes”, “no” 
or “if not, what suggestions do you have to improve the program?” which included space for a 
narrative response. One hundred percent of the respondents indicated that the quality of service 
they had received on the Wednesday MAT groups was “excellent” and two patient wrote a 
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narrative response in addition to circling “yes”, with one patient indicating that “having everyone 
[there] is perfect for what [they] need right now” and one patient suggesting “less cross 
talk/interruptions” (Table 1).  
 
Table 1 
 
 The second question asked, “Has the MAT program at CoRR met your needs?” The 
answer choices included “none of my needs have been met”, “only a few of my needs have been 
met”, “most of my needs have been met” and “almost all of my needs have been met.” Seventy-
six percent of respondents indicated “almost all of my needs have been met” and 24% indicated 
that “most of my needs have been met” (Table 2). 
Table 2 
17
0
2
0 2 4 6 8 10 12 14 16 18
Yes
No
Suggestions for Improvement
Q1: Would you rate the quality of service you 
have received on the Wednesday MAT group as 
"excellent"? 
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The third patient satisfaction survey question asked, “Have the services you received at 
CoRR helped you to deal more productively with your drug and/or alcohol program?” The 
answer choices included “No, they seemed to make things worse”, “No, they didn’t really help”, 
“Yes, they helped somewhat” and “Yes, they helped a great deal.” Eighty-eight percent of 
respondents indicated that the services they received at CoRR helped them “a great deal” in 
dealing more productively with their drug and/or alcohol program and 12% indicated that the 
services they received at CoRR “helped somewhat” (Table 3).  
 
Table 3 
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Q2: Has the MAT program at CoRR met your 
needs?
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Helped Somewhat
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Q3: Have the services you received at CoRR 
helped you to deal more productively with your 
drug and/or alcohol program? 
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 The fourth patient satisfaction survey question asked, “How satisfied are you with the 
amount of help you have received?” The answer choices included “very dissatisfied”, 
“indifferent or mildly dissatisfied”, “mostly satisfied” or “very satisfied.” Seventy-one percent of 
respondents indicated that they were “very satisfied” with the amount of help they had received 
and 29% indicated that they were “mostly satisfied with the amount of help they had received 
(Table 4).  
 
Table 4 
 
 
The last question asked if the respondent had “any suggestions for how the MAT program 
at CoRR can improve” and “What [they] liked about the program or think has been successful thus 
far?” and a space was provided for a narrative response. When examining the narrative responses 
to this question, several themes emerged such as the offering of additional MAT group days/times, 
more support (i.e. help with housing, finances, etc.) and many respondents left a positive response 
indicating that the program has met their needs. In addition, themes that emerged when patients 
discussed the benefits of MAT were it “gives you your life back”, controls cravings, decreases 
drug seeking behaviors, saves money, improved health and improved relationships (Curtis, Knapp 
0 2 4 6 8 10 12 14
Very Dissatisfied
Indifferent / Mildly Dissatisfied
Mostly Satisfied
Very Satisfied
Q4: How satisfied are you with the amount of 
help you have received?
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& Otten, 2019). At the time of collection for the initial patient satisfaction survey, the Wednesday 
MAT group had an average of 103 participant “sober days” (3 months).  
 A second patient satisfaction survey was collected at the completion of the DNP project in 
April 2019 yielding 25 respondents. The first question asked, “Would you rate the quality of 
service you have received on the Wednesday MAT group as “excellent”? Answer choices included 
“yes”, “no” or “if not, what suggestions do you have to improve the program?” which included 
space for a narrative response. One hundred percent of the respondents indicated that the quality 
of service they had received on the Wednesday MAT groups was “excellent” (Table 5).  
Table 5 
 
  
The second question asked, “Has the MAT program at CoRR met your needs?” The answer 
choices included “none of my needs have been met”, “only a few of my needs have been met”, 
“most of my needs have been met” and “almost all of my needs have been met.” Eighty-eight 
percent of respondents indicated that the MAT program at CoRR had met “almost all of my needs 
have been met” and 12% indicated that “most of my needs have been met” (Table 6).  
Table 6 
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1. Would you rate the quality of service you 
have received on the Wednesday MAT group as 
"excellent"?
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 The third patient satisfaction survey question asked, “Have the services you received at 
CoRR helped you to deal more productively with your drug and/or alcohol program?” The answer 
choices included “No, they seemed to make things worse”, “No, they didn’t really help”, “Yes, 
they helped somewhat” and “Yes, they helped a great deal.” Ninety-six percent of respondents 
indicated that the services that they received at CoRR helped them “a great deal” in dealing more 
productively with their drug and/or alcohol program and 4% of respondents indicated that the 
services they received “helped somewhat” (Table 7).  
 
Table 7 
 
0
5
10
15
20
25
None Few Most Almost All
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The fourth patient satisfaction survey question asked, “How satisfied are you with the 
amount of help you have received?” The answer choices included “very dissatisfied”, 
“indifferent or mildly dissatisfied”, “mostly satisfied” or “very satisfied.” One respondent left 
this question blank thus there were only 24 responses total for this question. Ninety-two percent 
of respondents indicated that they were “very satisfied” with the amount of help they had 
received and 8% indicated that they were “mostly satisfied with the amount of help they had 
received (Table 8).  
Table 8 
 
 
The last question asked if the respondent had “any suggestions for how the MAT program 
at CoRR can improve” and “What [they] liked about the program or think has been successful thus 
far?” and a space was provided for a narrative response. When answering what they liked about 
the program or think has been successful, many of the respondents wrote that they were thankful 
for the staff and felt like they “really care” and expressed that they were “getting their life back.” 
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4. How satisfied are you with the amount of help 
you have received? 
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In addition, many expressed that they felt the amount of support they received was a success of 
the program. Respondents also indicated that they felt the MAT program helped to lessen their 
cravings and keep them sober and that the program was patient centered and need based. 
Furthermore, several respondents indicated that they liked interacting with people that were also 
on Suboxone. Suggestions from respondents for how the MAT program at CoRR can improve 
were to offer more group times and provide more information on Suboxone.  
Provider Satisfaction Survey. An electronic, anonymous, provider satisfaction 
survey regarding the MAT Group program was created using Survey monkey and sent to the 
Medical Director, Nurse Practitioner, Substance Abuse Counselor and Clinical Coordinator at the 
completion of the DNP project at completion of the DNP project in April 2019 (Appendix P). The 
survey included three questions that allowed for the providers to answer in the narrative format. 
The survey yielded three responses.  
The first question asked what qualities the provider felt made a successful MAT program. 
The providers indicated that consistency, organization, adherence to clinical standards, patient 
centered care, boundaries, holistic care, flexibility and sustainable billing practices contributed to 
a successful MAT program.  
The second question asked what qualities providers felt made the MAT program at CoRR 
successful. The respondents indicated that the quality of care provided by the staff, teamwork, 
adherence to clinical standards, patient centered care, flexibility, active group meetings with 
counselors and providers, and comprehensive care for those with opioid use disorder made the 
MAT program at CoRR successful.  
The last question asked that providers indicate what they would like to see improve or 
change in regard to the MAT program at CoRR. Providers indicated that they would like to see the 
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implementation of electronic medical records and improved billing procedures. One respondent 
indicated they would like more extensive training on the policy and procedures at the clinic. In 
addition, respondents also indicated they would like to see the replication and expansion of the 
program in other areas and closer collaboration with other federally qualified health centers 
(FHQC’s). Lastly, the providers would like improved access to psychiatric care for patients and 
improved communication with the local hospital.  
 Demographic and Benchmark Data. At the initiation of the DNP project there were 47 
patients identified as eligible for participation in the MAT group program. The final number of 
participants were 35 as 12 never attended a MAT group on either day and were lost to follow-up 
or chose not to participate in the program. Patients were counted as being retained in the MAT 
group if they attended >2 MAT groups on either Tuesday or Wednesday. The data indicates that 
74% of patients were retained in the MAT group program at CoRR (Appendix P) which exceeds 
the recommended benchmark goal of 60% presented in the literature. There were 21 patients who 
attended the first MAT Wednesday group which exceeded the established objective for the project. 
To accommodate the increased number of MAT patients who expressed interest in this new group 
format an additional MAT group was created on Tuesdays. On average, there was about 12 patients 
who attended each respective MAT group. Participants were predominantly male at 63% male and 
37% female and the most common age range were those between the ages of 26-34 years old 
(Table 5). 
Table 5  
Demographic Data MAT Group (N=35)  
Gender  
Male 22 (63%) 
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Female 13 (37%) 
Age  
18-25 years old 2   (6%) 
26-34 years old 21 (60%) 
35-55 years old 11 (31%) 
55 or older  1    (3%) 
 
 The Nurse Practitioner obtained demographic data in the Summer of 2018 in regard to 
MAT patient race/ethnicity and Medi-Cal eligibility which can be found in the table below (Table 
6).  
Table 6 
MAT Demographic Data Summer 2018   
Race/Ethnicity  
White, non-Hispanic 41 (98%) 
Other  1 (2%) 
Medi-Cal Eligible   
Yes  27 (64%) 
No 15 (36%) 
 
(Curtis, Knapp & Otten, 2019) 
Section IV: Discussion 
Summary  
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 The implementation of the DNP project occurred over the course of four months at the 
CoRR Grass Valley campus. The over-arching aim of this DNP project was to improve health 
outcomes among underserved residents of Nevada county by increasing access to inter-
professional team-based MAT for opioid use disorder through the development of evidence 
based, interdisciplinary, nurse-managed MAT services through the initiation of the pilot program 
for the newly developed MAT patient delivery system and the development of evidence-based 
nurse practitioner process protocols. A measure of the success of the program and increasing 
access to MAT services for this patient population, was meeting the benchmark goal of 60% for 
patient retention in the program. The data from this project indicated that there was a 74% 
retention rate in the MAT group program at CoRR which meets the benchmark goal of 60% 
suggested in the literature. In addition, the targeted patient population were underserved 
members of a non-metropolitan community and as previously discussed, Nevada and Placer 
counties have high rates of opioid use disorder with limited access to MAT services. The project 
implementation served patients with opioid use disorder from both counties which met the goal 
of increasing access to MAT services for this under resourced group.  
 Furthermore, the initial patient satisfaction survey results regarding the nurse managed, 
interdisciplinary MAT group were positive with 100% of the respondents indicating that the 
quality of service they had received on the Wednesday MAT groups was “excellent” and 76% 
respondents indicated “almost all of my needs have been met” by the MAT program at CoRR. In 
addition, a majority of the patients indicated that the MAT program and helped them deal more 
productively with their drug and/or alcohol program and were satisfied with the amount of help 
that they had received. Due to the overwhelming positive feedback from the MAT patients at 
CoRR, a second team-based MAT group was added on Tuesdays. In addition, the Medical 
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Director at CoRR indicated that there were plans to expand the newly developed collaborative 
MAT group format to other CoRR campuses.  
 The data indicates a significant need for nurse-managed community-based MAT services, 
especially in non-metropolitan Northern California counties, where opioid overdose rates remain 
high and access to services limited. This DNP project has assisted in bringing needed MAT 
services to this underserved non-metropolitan community, and in turn improved health 
outcomes, where the number of residents with opioid use disorder remains high.  
Interpretation  
 The findings of this DNP quality improvement project found positive and successful 
outcomes from the nurse-managed community-based medication assisted treatment services for 
underserved patients with an opioid use disorder in a non-metropolitan Northern California 
county. The findings were consistent a study conducted by Jones (2018) stating that MAT in 
conjunction with psychosocial treatment has been shown to be the most effective evidenced 
based treatment option for this patient population (Jones, 2018).  
 The treatment of opioid use disorder is multidimensional and requires a comprehensive, 
interdisciplinary approach when providing MAT services. Employing nurse-managed, 
collaborative community-based medication treatment services for underserved patients with 
opioid use disorder in non-metropolitan communities allows for integrative treatment and 
improved health outcomes and patient satisfaction. This supports the ecological framework that 
guided this DNP project as the fundamentals of this perspective are supporting all levels of a 
health problem. The interventions of this project addressed the intrapersonal, interpersonal, 
institutional/organizational and community factors of the individual with opioid use disorder.  
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 Although the research discussed in this DNP paper states that best practice is MAT in 
conjunction with psychosocial treatment, some recent research brings this idea into question. The 
field of substance abuse, and medication assisted treatment, is ever evolving and remains new 
and thus further research is needed regarding the role of behavioral health in conjunction with 
MAT. In addition, further research is needed regarding nurse-managed, interdisciplinary 
medication assisted treatment for opioid use disorder in underserved non-metropolitan 
communities who remain at high risk.  
Limitations 
A limitation of this DNP project was the shortage of available providers/prescribers who 
possessed a waiver to prescribe or dispense buprenorphine. The Drug Addiction Treatment Act 
of 2000 (DATA 2000) requires that qualified practitioners apply for a waiver to treat opioid 
dependency with approved buprenorphine products after meeting specific criteria. Once a waiver 
is obtained, they can treat no more than 30 patients at a time within the first year (Substance 
Abuse and Mental Health Services Administration, 2019). This limited the amount of MAT 
patients that could be seen as there were at minimum two providers present at a time who carried 
a waiver to prescribe Buprenorphine limiting the number of patients that could be prescribed 
opioid agonist treatment to a maximum of 60.  Strategies to mitigate this potential barrier would 
be to increase the MAT trainings for providers to ensure adequate staffing and collaborate with 
the CEO and other stakeholders to ensure continued staff development and growth and support 
for all team members (SAMHSA-HRSA Center for Integrated Heath Solutions, 2014) 
Another limitation of this project were the attitudes and beliefs of some counselors and 
members of other support groups in regard to the use of medications in the treatment of opioid 
use disorder (i.e. buprenorphine). In speaking with the MAT patients during groups and 
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privately, multiple patients shared that they were told that because they were on Buprenorphine 
as adjunctive therapy in the treatment of their opioid use disorder they were not considered to be 
“sober” and they were discouraged from using the medication. To address this potential barrier, 
providers could provide education to all members of the health care team regarding the 
medications that are used in MAT, present the data supporting its use, and reinforce education 
provided to patients regarding the use of medication to support their recovery. 
The third limitation of the project was the time frame for delivery. Although the project 
was implemented over a four-month time period, the DNP student/project manager was only able 
to attend 2-3 Wednesday MAT groups a month due to scheduling conflicts with her primary 
employer. The added Tuesday MAT group was not attended by the DNP student. This could 
have had an effect on the results of the project and being present for the implementation of all 
MAT groups would have been ideal.  
Conclusion 
MAT has proven to be the most effective evidence-based treatment option for patients 
with opioid dependence combined with psychosocial treatment. Treatment of opioid misuse 
disorder with buprenorphine and naloxone and/or buprenorphine has been proven to be safe and 
an effective treatment option in the office-based setting to decrease opioid use and cravings. It 
can also be correlated to lower transmission rates of communicable diseases such as hepatitis c 
and decreased numbers of heroin overdose deaths. In addition, recent data suggests that counties 
with high overdose rates, such as certain rural Northern California counties, have decreased 
access to opioid treatment programs. The implementation of a nurse managed, community-based 
MAT program for underserved patients in non-metropolitan communities would assist in 
alleviating this issue by increasing access to these much-needed services.  
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This nurse-managed, community-based care model for providing MAT services to 
underserved patients in nonmetropolitan areas combines best practice in treating opioid use 
disorder and provides comprehensive and collaborative care which yields positive health 
outcomes and supports recovery.  This is further supported by the positive findings of this project 
with a MAT retention rate which met the benchmark goal and overwhelmingly positive results of 
the patient satisfaction survey that was administered regarding the MAT services provided. The 
project implementation and model are reproducible as evidenced by addition of the Tuesday 
MAT group as well as plans to expand the newly developed MAT group to other campuses 
within the CoRR organization. Particularly, the role of the Nurse and Nurse Practitioner is 
essential to connecting these high-risk, vulnerable communities with needed MAT services to 
improve health outcomes and counteract the devastating effects of the opioid epidemic.  
Due to the new and evolving nature of the field of substance abuse and medication 
assisted treatment, it would be beneficial to obtain further research regarding best practices for 
providing MAT services to underserved non-metropolitan communities.  
Section V: Other Information 
Funding 
 This DNP project was funded through personal savings as indicated in the budget. The 
clinic site implementation site, Community Recovery Resources (CoRR), receives funds through 
the Hub and Spoke grant through Aegis. There are no other financial disclosures related to this 
DNP project.  
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Appendix B: Letter of Approval from Community Recovery Resources (CoRR) Grass Valley 
 
 
 
 
 
 
 
To Whom It May Concern: 
 
Lauren Knapp, University of San Francisco BSN-DNP/FNP student, has been approved to 
initiate her DNP project regarding the development and implementation of nurse-managed, 
community-based medication assisted treatment services at the Community Recovery Resources 
Grass Valley campus.  
 
The student is granted permission to utilize the conference room and clinical space at the Grass 
Valley campus for the implementation of her DNP clinical improvement project.  
 
Sincerely,  
 
 
Michelle Otten 
Medical Services Coordinator, 
Grass Valley Residential  
Community Recovery Resources 
www.corr.us 
 
Tel: (530) 273-9541 ext. 234 
Fax: (530) 271-7036 
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Appendix C: SWOT Analysis 
 
 
Strengths
• Addresses the problem of inadequate 
access to MAT services for opioid 
dependent patients in non-metropiltan 
communities 
• The potential impact the 
implementation of nurse-managed 
MAT services would have on illicit 
and prescription opiod related deaths
• The potential cost savings in 
decreased uilization of inpatient and 
detoxification services and 
• The potential for decreased rates of 
communicable diseases (i.e. Hepatitis 
C)
• Increased distribution of Narcan kits 
to the community and high risk 
groups
Weaknesses
• Lack of patient transportation to 
CoRR Grass Valley for treatment
• Patients not covered by the H&S 
grant unable to pay for MAT services 
• Lack of waivered prescribers to meet 
the treatment needs of the patients 
• Patient adherence to Suboxone 
induction/maintenance therapy 
• Patient demographics (i.e. unstable 
housing, distance from clinic, lack of 
support system)
Opportunities
• Provide increased access to MAT 
services to a high risk non-
metropolitan community
• Provide education to patients, family 
and the community regarding the use 
of Narcan and it's life-saving capability 
• Reduce the number of illicit and 
prescription related deaths 
• Continued H&S grant funding for 
MAT services 
• Reducttion in the transmission of 
communicable diseases in this high risk 
population through opioid agonist 
medication adherence and education
Threats
• Loss of H&S funding
• Opioid dependent patients in need of 
MAT services unable to access 
treatment 
• Pharmacy out of stock of opioid 
agonist medication
• Patient leaves MAT treatment
• No change in illicit and opioid related 
deaths  
• Loss of waivered prescibers
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Appendix E: Grant Reporting Monthly Invoice Form  
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Appendix F: Budget and Cost Benefit Analysis  
 
Budget 
 
Societal Costs of Prescription Opioid Abuse, Dependence and Fatal Overdose, United 
States (Millions of 2013 Dollars) 
Nonfatal Costs  Costs (Range based on 95% CI of 
prevalence) 
Health care  $26, 075     ($21,372-$30,778) 
Substance Abuse Treatment  $2,820        ($2,567-$3,245) 
Criminal Justice  $7, 654       (public sector costs) 
Lost Productivity  $20, 441     (%17,286-$23,751) 
Total Nonfatal Costs  $56,990      ($48,879-$65,428) 
Fatal Costs  $21,513      ($21,182-$21,844) 
Total Nonfatal and Fatal Costs  $78, 503 
 
Direct Costs 
Item Description  Unit Cost  Total Cost  
Materials (patient and provider 
surveys, handouts, 24 pk box of 
ballpoint pens) 
$59.99 for 100 full-color, 
single sided flyers 
 
$5.79 for 24 pk box of black 
Bic ballpoint pens  
$66 (Paid for by NP) 
Coffee and Donuts on the first 
day of the MAT Wednesday 
Pilot Program  
Starbucks Coffee Traveler 
$12.95 per box (Serves 12) 
(2 boxes = $26) 
 
$20 for 2 dozen Donuts 
from B.J. Cinnamon Donut 
Shop in Folsom, CA  
$50 (Paid for by NP) 
NP Travel Cost (mileage/gas) 98 miles/week  
$30 per week (2 
Wednesdays/month) x 4 
months 
$240 (Paid for by NP) 
 Total $356 
Indirect Costs  
Item Description  Unit Cost  Total Cost  
NP Project 
management/implementation  
$61/hour x 8 hrs/week (2 
Wednesdays/month) x 4 
months  
$3,904 (NP services/project 
management provided at no 
cost)  
TOTAL PROJECT 
EXPENSES  
(Direct + Indirect Costs) 
 $4,260 
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Florence, C., Luo, F., Xu, L., & Zhou, C. (2016). The economic burden of prescription opioid 
overdose, abuse and dependence in the united states, 2013. Medical Care, 54(10), 901-906.  
 
Cost Benefit Calculation 
• Total nonfatal cost of prescription opioid misuse $58 billion  
o This number includes: 
▪ Increased healthcare and substance abuse treatment costs by $29.4 billion 
▪ Increased criminal justice costs by $7.8 billion  
▪ Reduced productivity among those who do not die of overdose by $20.8 
billion (2015)  
o Total nonfatal cost of $58 billion  1.9 million people in the U.S. with a 
prescription opioid disorder in 2013 = average cost of $30,000 
                                *Average cost estimates for prescription opioid disorders only 
                                 (Council of Economic Advisors, 2017) 
 
Cost Benefit Ratio 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Average nonfatal cost of a person with a 
prescription opioid disorder in the U.S. in 2013 
 $ 30,000 
Projected cost for project implementation for one 
year  
$ 12,779 
$30,000/$12,779 = 2.35 
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Appendix G: Work Breakdown Structure  
 
 
 
 
 
 
 
  
The Development and Implementation of Nurse-
Managed Community-based Medication Assisted 
Treatment Services for an Underserved Non-
Metropolitan Northern California Community 
Phase 2
Meet with the Medical 
Director, NP, PA and 
Clinical Coordinator and 
stakeholders at CoRR to 
propose the clinical 
improvement project
Phase 3
Develop updated MAT  
prescribing policies for 
opioid agonist medications 
(i.e. Suboxone), patient 
and provider resources, 
structured Wednesday 
MAT group classes
Phase 4
Evauate the success of the 
project implementation 
through established 
outcome measures and 
patient and provider 
satisfaction surveys
Phase 1
Conduct research on 
opioid epidemic in the U.S. 
and best practices for 
MAT services 
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Appendix H: Communication Plan  
 
Information Audience  When  Communication 
Method 
DNP project 
development and 
coordination  
DNP Chair, CoRR 
Clinical Coordinator, 
CoRR MD, FNP, PA 
Weekly  In-person meeting, 
Email, Cell phone  
DNP project status 
and any barriers 
encountered  
DNP Chair, CoRR 
Clinical Coordinator 
Weekly  In-person meeting, 
Email, Cell phone 
DNP project 
revisions  
DNP Chair, CoRR 
Clinical Coordinator 
As needed  In-person meeting, 
Email, Cell phone 
DNP project 
milestones  
DNP Chair and 
Committee Member  
Monthly  In-person meeting, 
Zoom, Email 
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Appendix I: Gap Analysis  
 
 
 
 
 
Desired State 
• Increase access to nurse managed, community based medication-
assisted therapy for opioid dependence at Community Recovery 
Resources (CoRR) Grass Valley to decrease the rates of illicit and 
prescription opioid misuse and prescription opioid related death 
rates and optimize and support the patient's overall health and 
well-being. 
Current State
• Community Recovery Resources (CoRR) Grass Valley is 
currently developing their medication-assisted therapy program 
for opioid dependence, through the H&S Grant funding, and 
there is an opportunity to incease access to these services for 
those that are opioid dependent in the community. 
Action Plan 
• Conduct a review of the literature for medication-assisted therapy best 
practices, identify demographic data related to illicit and prescription 
opioid misuse and related death rates to idenitfy high risk populations
• Meet with CoRR treatment team and stakeholders and present 
proposed implementation project 
• Develop updated prescribing policies, patient and provider resources, 
structured Wednesday clinic days w/interprofessional team
• Evaluate the effectivess of the project by number of patients seen, 
responses from the patient and provider satisfaction survey provided, 
the retention rate for patients in the program with a benchmark goal 
of 60% and this information will be assembled over a three month 
period.
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Appendix J:  GANTT Chart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10/1/18 11/20/18 1/9/19 2/28/19 4/19/19
Conduct a literature review
Meet with stakeholders, assemble Committee Chair and
Committee Member
Identify patients to be enrolled in MAT Wednesday Groups
Develop updated MAT group policies and workflows,
updated prescribing policies, process protocols and patient
and provider resources
Project Implementation
Data collection and analysis
Complete written DNP project and disseminate results to USF
faculty
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Appendix K: MAT Wednesday Pilot Program Schedule, CoRR Grass Valley 
 
MAT Wednesday Pilot Program Schedule 
CoRR Grass Valley 
 
0800-0900 Flash Meeting, MAT meeting 
 
0900-0930 Patient’s arrive, UDS testing (to be completed before or after MAT class) 
 
1000-1100 MAT Group Class 
  Location: Conference room #104 
  Instructors: Steve and Natalie 
  6-10 patients initially 
 Mandatory attendance—patient unable to receive medication refill if not in  
attendance  
 
1100-1130 Patient UDS testing, if not already completed prior to MAT class 
Patients that have any concerns with their maintenance dose of Suboxone or any 
clinical concerns can be seen by a provider at this time 
 
1200-1300 Lunch 
 
 
1300-1700 Clinic    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lauren (USF FNP student) will bring refreshments to the first group and patients can be 
given an extra gas card for attendance.  
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Appendix L:  Updated Maintenance Therapy Suboxone Progress Note for MAT Group  
Community Recovery Resources 
Maintenance Therapy Progress report – Suboxone (buprenorphine/naloxone) 
 
Community Recovery Resources                  Scott Kellerman MD 
159 Brentwood Drive                    Ca License # 
Grass Valley, CA  95945                      DEA:  
Ph. (530) 273-9541 / Fax (530) 273-7740     DEA:  
 
 
Patient Name: ___________________________ DOB: ___________ Date: ___________ 
 
Prior drug of choice: __________________________ COWS: __________ 
 
Chief Complaint_______________________________________________________________ 
 
HPI: 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
 
Urine Drug Screen results: 
__________________________________________________________ 
Patient indicates they would like to be seen by provider after MAT group? □ yes  □ no   
I feel like using right now: not at all – mild – moderate – severe 
 
I rate my level of withdrawal: not at all – mild – moderate – severe 
 
Suboxone dose: ________mg   Taken: Once daily Twice daily Three times daily      
 strips  tabs 
Refilled at what interval: ____________ 
 
Preferred pharmacy: ______________________________________________ 
 
Date of last Cures report: __________________ 
 
Have you used alcohol since last visit: Yes   No 
If “Yes” how much and when: _______________________________________ 
 
Appearance/mental status_______________________________________________________ 
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Neuro/Psyche (tremor/jerks/follows commands) ______________________________________ 
 
 
Recent Lab Results: _________________________________________________________ 
 
Diagnosis: 
1._____________________________________________________________________       
2._____________________________________________________________________       
3._____________________________________________________________________       
4._____________________________________________________________________ 
 
Narcan available? Yes   No 
 
Lab Ordered:  Yes    No 
Urine Drug Test (5-8 Items), CBC/differential, comprehensive chemistry panel, GGT, hepatitis B 
surface antigen - (if positive - reflex to hepatitis quantitative HBV DNA levels), hepatitis B core 
antibody - (if positive - reflex to quantitative HBV DNA levels), hepatitis B surface antibody , 
Hepatitis C antibody - (reflex to quantitative HCV RNA level if positive), Chlamydia/Gonorrhea, 
HIV, RPR   
If female – pregnancy test.  Additional labs: 
_____________________________________________ 
 
Treatment: (drug/dose/frequency/duration) 
1._Suboxone: 
_____________________________________________________________________________ 
2.____________________________________________________________________________ 
3.____________________________________________________________________________ 
4.____________________________________________________________________________ 
5.____________________________________________________________________________ 
 
Notes: 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
Consults/therapy/counseling ordered:  Yes    No     
If Yes to whom? ______________________ 
 
Referral to Primary Care: Yes   No   Pt has ongoing outpatient care Provider   
If Yes to whom? _______________________ 
 
Return to clinic: 1 week 2 weeks   3 weeks 4 weeks prn other_____________________ 
 
 
Provider Signature: ______________________________________ 
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Appendix M: CoRR Wednesday MAT Group Protocol  
 
 
Community Recovery Resources (CoRR) 
Wednesday MAT Group Protocol 
I. Criteria for Wednesday MAT group participation  
A. The patient meets DSM 5 diagnostic criteria for moderate or severe opioid use     
disorder 
B. The patient has completed the induction phase of Suboxone and has   
demonstrated relative stability on their maintenance dose of Suboxone 
C. The patient does not have any prior job commitments that would hinder their  
ability to be present for the Wednesday MAT group 
D. Attendance for Wednesday MAT group is mandatory, patient will be unable  
to receive medication refill if not in attendance.  
II. Workflow for Wednesday MAT group 
A. Each patient will check in 15-30 minutes prior to the start of each group  
and provide a urine sample for the urine drug screen (UDS). If the patient is 
unable to provide a urine sample prior to the start of the group, a urine sample 
will be required for the UDS immediately following the group.  
1. All urine drug screen results will be recorded and given to the  
health care provider as soon as they are available.  
B. The health care team comprised of the Counselor(s), MAT Program Director,  
Medical Assistant, Physician, Nurse Practitioner and Physicians Assistant will all 
be present during the Wednesday MAT group. 
C. All patient’s charts who are participating in the Wednesday MAT group will be  
pulled and brought to conference room number 104 at the start of each group and 
be accessible to the health care provider(s) to chart assessments, progress notes 
and write medication refill orders. 
D. Prior to the start of the group, patients will complete a short questionnaire  
regarding any issues they are having with recovery, cravings/withdrawal 
symptoms, request for a change in medication dosage and/or a request to meet 
with their health care provider after the group. After the questionnaire is 
completed by the patient, each questionnaire will be given to the respective health 
care provider.  
E.  MAT group meeting will be conducted by Counselor (Natalie or Steve) 
F. Following the MAT group, patients who requested to see the health care provider,  
or have an existing appointment with the provider, will be roomed and seen.  
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Appendix N: Standardized Procedures for the Nurse Practitioners at Community Recovery  
                      Resources (CoRR) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STANDARDIZED PROCEDURES FOR THE 
NURSE PRACTITIONERS AT 
 
 
Community Recovery Resources (CoRR) 
Grass Valley Campus 
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INTRODUCTION TO THE STANDARDIZED PROCEDURES  
 
 
The purpose of these Standardized Procedures is to define the scope of practice of  
Nurse Practitioners at Community Recovery Resources (CoRR) in order to meet the legal 
requirements for the provision of health care by nurse practitioners.  They are established to 
assist all health care providers with an understanding of the role and scope of practice of the 
nurse practitioner and to provide a safeguard so that providers and patients alike may be assured 
of the best health care possible. 
 
These Standardized Procedures are based on the Guidelines established by the Board of 
Registered Nursing and the codes and regulations circumscribing California nurse practitioners 
(collectively referred to as the Nursing Practice Act). In order to provide the highest standard of 
care, these Standardized Procedures incorporate the following qualities: 
 
ADAPTABILITY, in order to allow for the unique management needs of each individual 
patient; 
FLEXIBILITY, to accommodate the rapidly changing and complex nature of the health care 
field and to acknowledge that medicine is not an exact science; 
PRACTICALITY, in order to be useful in a setting that must incorporate a variety of 
educational backgrounds and personal management styles; and 
SPECIFICITY, to address the intent of the Standardized Procedure Guidelines, the codes 
regulating nurse practitioners and to protect the health care consumer. 
 
The Standardized Procedures consist of the following:  
 
 GENERAL POLICIES:  Define the general conditions of and give authorization to the 
nurse practitioner to implement the Standardized Procedures. 
 
 HEALTH CARE MANAGEMENT STANDARDIZED PROCEDURES:  Delineate the 
medical functions requiring a standardized procedure and, using policies and protocols, 
define the circumstances and requirements for their implementation by the nurse practitioner. 
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STATEMENT OF APPROVAL AND AGREEMENT  
 
This document was jointly developed and approved by the CoRR Medical Director, Dr. Scott 
Kellerman, and the clinical practice team, for Nurse Practitioners in accordance with the codes 
regulating nursing practice, on  ____[date]___________________.  
 
Signature on this statement implies 
• Approval of the Standardized Procedures and all the policies and protocols contained in 
this document.  
• Agreement to maintain a collaborative and collegial relationship. 
• Agreement to abide by the Standardized Procedures in theory and practice. 
 
 
______________________________________________________________ 
Name/Title          Date  
 
 
______________________________________________________________ 
Name/Title          Date 
 
 
______________________________________________________________  
Name/Title          Date 
 
 
______________________________________________________________ 
Name/Title         Date 
 
 
______________________________________________________________ 
Name/Title         Date 
 
 
______________________________________________________________  
Name/Title         Date 
 
 
______________________________________________________________  
Name/Title         Date 
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GENERAL POLICIES  
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GENERAL POLICIES 
 
It is the intent of this document to authorize nurse practitioners at Community Recovery 
Resources (CoRR) to implement the Standardized Procedures without the immediate supervision 
or approval of a physician. The Standardized Procedures, including all the policies and protocols, 
are defined in this document and will be referred to generally as the "Standardized Procedures".   
 
 
DEVELOPMENT, APPROVAL, REVISION AND REVIEW 
 
The Standardized Procedures have been collaboratively developed and approved by the Nurse 
Practitioners, Medical Director and CEO of CoRR. Review, and if necessary, revision, of the 
Procedures will be done yearly by the Nurse Practitioner, the Medical Director and the CEO at 
CoRR. The completion of these tasks, including notification of revisions, is the responsibility of 
the Nurse Practitioners, the Medical Director and the CEO at CoRR.  
 
AGREEMENT  
 
All nurse practitioners and associate physicians will signify agreement to the Standardized 
Procedures following the approval process.  Signature on the Statement(s) of Approval and 
Agreement implies the following: approval of all the policies and protocols in this document, the 
intent to abide by the Standardized Procedures, and the willingness to maintain a collegial and 
collaborative relationship with all the parties.   
 
SETTING  
 
The nurse practitioners will perform these Standardized Procedures at Community Recovery 
Resources (CoRR), in Auburn, Grass Valley, Lincoln, Roseville, Kings Beach and Truckee  
campuses. 
 
RECORD OF AUTHORIZED NURSE PRACTITIONERS  
 
The Statement of Approval and Agreement signed by the nurse practitioners will act as the 
record of nurse practitioners authorized to implement the Standardized Procedures. 
 
EDUCATION AND TRAINING  
 
The nurse practitioners must have the following: 
• Possession of a valid California License as a Registered Nurse. 
• Certification by the State of California, Board of Registered Nursing as a Nurse 
Practitioner.  
• Furnishing Number. 
• DEA Number. 
• Certification by a national certifying body (AANP or ANCC). 
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EVALUATION OF CLINICAL CARE  
 
Evaluation of the nurse practitioner will be provided in the following ways: 
 
INITIAL EVALUATION 
• Performed at 3 and 6 months through feedback from colleagues and chart review of patient care 
delivered during the evaluation period.  
 
CONTINUING EVALUATION 
• Annual evaluation based on feedback from colleagues and chart review of patient care 
delivered during the evaluation period. 
• Verification of current licensure and certifications. 
 
PATIENT RECORDS 
  
The nurse practitioner will be responsible for the preparation of a complete medical record for 
each patient contact per existing office policies. 
 
SUPERVISION 
 
The nurse practitioner is authorized to implement the Standardized Procedures in this document 
without the direct or immediate observation, supervision or approval of a physician. Physician 
consultation is available at all times, either on-site, by phone or electronically. 
 
CONSULTATION 
 
The nurse practitioner will be providing health care as outlined in this document.  In general 
communication with a physician will be sought for all the following situations, and any others 
deemed appropriate.  Whenever a physician is consulted, a notation to that effect, including the 
physician's name, must be made in the chart.  
 
• Whenever situations arise which go beyond the intent of the Standardized Procedures or 
the competence, scope of practice, or experience of the nurse practitioner. 
• Whenever patient conditions fail to respond to the management plan as anticipated. 
• Any patient with acute decompensation or rare condition. 
• Any patient conditions which do not fit the commonly accepted diagnostic patterns for a 
disease or disorder. 
• At the patient's, nurse practitioner's or physician's request.  
• All emergency situations after initial stabilizing care has been started. 
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HEALTH CARE MANAGEMENT 
STANDARDIZED PROCEDURES 
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HEALTH CARE MANAGEMENT - PRIMARY CARE 
 
 
POLICY 
 
Primary Care includes acute and episodic conditions, chronic conditions, and health care 
maintenance. Medication-based therapies for opioid use disorder and substance use disorder 
detoxification are included under primary care in this standardized procedure. The nurse 
practitioner is authorized to diagnose and manage Primary Care conditions under the following 
protocols: 
 
 
PROTOCOLS 
 
1) Assessment and treatment plan is developed consistent with accepted clinical guidelines 
available through the practice resources listed in this document. 
 
2) Lab work and diagnostic studies ordered are appropriate to the condition being evaluated 
and consistent with internal practice policies 
 
3) Durable medical goods and therapies ordered, such as physical therapy, occupational 
therapy, dietary counseling and psychological services, are appropriate to the condition 
and consistent with internal practice policies.  
 
4) Patient education and follow up is provided as appropriate. 
 
5) All other applicable Standardized Procedures in this document are followed during health 
care management.  
 
6) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient 
Records, Supervision and Consultation in these Standardized Procedures are in force. 
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 HEALTH CARE MANAGEMENT - SECONDARY CARE 
 
 
POLICY 
 
Secondary Care conditions are unfamiliar, uncommon, unstable or complex conditions. The 
nurse practitioner is authorized to evaluate and treat Secondary Care conditions under following 
protocols: 
 
 
PROTOCOLS 
 
1) Assessment to the level of surety plus appropriate differential diagnosis.  
 
2) A physician is communicated with regarding the evaluation, diagnosis and/or treatment 
plan.  
 
3) Management of the patient is either in conjunction with a physician or by complete 
referral to a physician or other treatment center. 
 
4) The physician is notified if her/his name is used on a referral to a specialty physician or 
department.  
 
5) The consultation or referral is noted in the patient's chart including name of physician. 
 
6) All Secondary Care charts are co-signed by a physician.  
 
7) All other applicable Standardized Procedures in this document are followed during health 
care management. 
 
8) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient 
Records, Supervision and Consultation in these Standardized Procedures are in force. 
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HEALTH CARE MANAGEMENT - TERTIARY CARE 
 
 
POLICY 
 
Tertiary Care conditions are acute, life-threatening, emergency conditions.  The nurse 
practitioner is authorized to evaluate Tertiary Care conditions under the following protocols: 
 
 
PROTOCOLS 
 
1) Initial evaluation and stabilization of the patient may be performed with concomitant 
notification of a physician or emergency department, and immediate referral.  
 
2) The referral is noted in the patient's chart including name of physician and/or facility 
referred to. 
 
3) All other applicable Standardized Procedures in this document are followed during health 
care management. 
 
4) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient 
Records, Supervision and Consultation in these Standardized Procedures are in force. 
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PROCEDURES AND MINOR SURGERY 
 
 
POLICY 
 
The nurse practitioner may perform the listed procedures under the following protocols:  
 
• Chemical or electrocautery of external, non-facial, non-malignant lesions less than 
1cm in size, e.g. warts. 
• Foreign body removal, simple removal from the skin.  
• Epidermal cyst removal (non-facial) less than 3 cm in size. 
• Incision and drainage of non-facial abscess less than 5 cm in size. 
• Suture non-facial laceration less than 5 cm in size. 
• Toenail removal. 
• IUD insertion. 
• Nexplanon insertion. 
 
PROTOCOLS 
 
1) The nurse practitioner has been trained to perform the procedure(s), has been 
observed satisfactorily performing the procedure(s) by another provider competent in 
that skill, and continued competency is assessed per written criteria. 
 
2) The nurse practitioner is following standard medical technique for the procedures as 
described in the Resources listed in this document.  
 
3) Appropriate patient consent is obtained before the procedure. 
 
4) All other applicable Standardized Procedures in this document are followed during 
health care management. 
 
5) All General Policies regarding Review, Approval, Setting, Education, Evaluation, 
Patient Records, Supervision and Consultation in these Standardized Procedures are 
in force.  
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FURNISHING DRUGS AND DEVICES 
 
 
POLICY 
 
The nurse practitioner is authorized to furnish drugs and devices under the following protocol: 
 
 
III. PROTOCOL  
 
1) The nurse practitioner has a current furnishing number.  
 
2) The Standardized Procedure was developed and approved collaboratively by the medical 
director and nurse practitioner clinical care team. 
 
3) All drugs and devices ordered are limited to the recommendations in the clinical 
resources listed in this document. 
 
4) The drugs and devices ordered are consistent with the nurse practitioner’s educational 
preparation or for which clinical competency has been established and maintained. 
  
5) The drug or device ordered is appropriate to the condition being treated.  
 
6) Patient education is given regarding the drug or device. 
 
7) The name, title, and furnishing number of the nurse practitioner is written on the 
transmittal order. 
 
8) The Statement of Approval and Agreement signed by the nurse practitioners will act as 
the record of nurse practitioners authorized to furnish.  
 
9) No single physician will supervise more than four furnishing nurse practitioners at any 
one time. 
 
10) A physician must be available at all times in person, electronically or by telephone.  
 
11) All other applicable Standardized Procedures in this document are followed during health 
care management. 
 
12) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient 
Records, Supervision and Consultation in these Standardized Procedures are in force.  
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 ORDERING SCHEDULED CONTROLLED SUBSTANCES 
 
 
POLICY 
 
The nurse practitioner is authorized to order scheduled controlled substances per the following 
protocols: 
 
 
PROTOCOLS 
 
General 
 
1) The nurse practitioner follows the provisions of the Standardized Procedure for 
Furnishing. 
 
2) The nurse practitioner’s name, title, furnishing and DEA numbers are on a secure 
transmittal order. 
 
3) Relevant scheduled drug contracts, DEA requirements, and all State and Federal 
regulations are adhered to.  
 
4) A CURES report is run on each patient receiving a controlled substance.  
 
5) Schedule III and II substances are ordered following the Patient Specific Protocol (i.e. 
Medication Assisted Therapy (MAT) protocol, Buprenorphine Induction Protocol, 
Alcohol Withdrawal (Mild-Moderate) Protocol)  
 
6) All other applicable Standardized Procedures in this document are followed during health 
care management. 
 
7) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient 
Records, Supervision and Consultation in these Standardized Procedures are in force.  
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MEDICATION MANAGEMENT 
 
 
POLICY 
 
The nurse practitioner is authorized to manage drugs and devices under the following protocols: 
 
 
PROTOCOLS 
 
1) The management of drugs or devices includes evaluating, initiating, altering, 
discontinuing, furnishing and ordering of prescriptive and over-the-counter medications.  
 
2) Medication evaluation includes  assessment of: 
• Other medications being taken. 
• Prior medications used for current condition. 
• Medication allergies and contraindications, including appropriate labs and exams. 
• Cures report (Cures report run every 3 months per clinic policy) 
 
4) The drug or device is appropriate to the condition being treated, and: 
• Accepted dosages per references. 
• Generic medications are ordered if appropriate. 
 
5) A plan for follow-up and refills is written in the patient's chart. 
 
6) The prescription must be written in patient's chart including name of drug, strength, 
instructions and quantity, and signature of the nurse practitioner. 
 
7) All other applicable Standardized Procedures in this document are followed during health 
care management. 
 
8) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient 
Records, Supervision and Consultation in these Standardized Procedures are in force. 
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IV. DISPENSING MEDICATIONS 
 
 
POLICY 
 
The nurse practitioner may dispense pre-packaged prescription drugs and devices, including 
Schedule II-V controlled substances under the following protocols: 
 
 
PROTOCOLS 
 
1) The drug or device utilizes required pharmacy containers and labeling.  
 
2) All appropriate record keeping practices of the dispensary are performed.  
 
3) All State and Federal policies on dispensing Controlled Substance must be followed. 
 
4) All other applicable Standardized Procedures in this document are followed during health 
care management. 
 
5) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient 
Records, Supervision and Consultation in these Standardized Procedures are in force. 
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A. COMPLIMENTARY SAMPLES 
 
 
V. POLICY 
 
The nurse practitioner is authorized to sign for the request and receipt of complimentary samples 
of prescription drugs and devices under the following protocols: 
 
 
VI. PROTOCOLS 
 
1) The list of Authorized Pharmaceutical Samples for Nurse Practitioner Signature is kept in 
a secured area in the Clinical Coordinator’s office.   
 
2) Each written request shall contain the name and address of the supplier and the requester, 
the name and quantity of the specific dangerous drug desired, the name of the nurse 
practitioner receiving the samples, the date of receipt, and the name and quantity of the 
dangerous drugs or devices provided.  These records shall be preserved by the supplier. 
 
3) A review of this process will be part of the review of all the Standardized Procedures.   
 
4) All other applicable Standardized Procedures in this document are followed during health 
care management. 
 
5) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient 
Records, Supervision and Consultation in these Standardized Procedures are in force. 
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VII. AUTHORIZATIONS 
 
 
VIII. POLICY 
 
The nurse practitioner is authorized, under the following protocols, to: 
 
• Assess Worker’s Compensation injuries and illnesses.  
• Certify Disability. 
• Manage Home Health and Personal Care Services. 
 
IX. PROTOCOLS 
 
1) Workers’ Compensation.  The Doctor’s First Report of Occupational Injury or Illness, 
co-signed by the nurse practitioner, for a workers’ compensation claim can be for a 
period of time off from work not to exceed three calendar days.  The treating physician 
is required to sign the report and to make any determination of any temporary disability. 
 
2) Certify Disability.   The nurse practitioner has performed a physical exam and 
collaborated with a physician and surgeon.   
 
3) Home Health and Personal Care Services.  Approval, signing, modifying, or adding to a 
plan of treatment or plan of care is after consultation with the treating physician and 
surgeon.  
 
4) All other applicable Standardized Procedures in this document are followed during 
health care management. 
 
5) All General Policies regarding Review, Approval, Setting, Education, Evaluation, 
Patient Records, Supervision and Consultation in these Standardized Procedures are in 
force. 
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RESOURCES 
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RESOURCES 
 
 
In House Protocols: 
• Medication-based therapies for opioid use disorder protocols  
• Substance use disorder detoxification protocols 
 
Examples of References: 
 
• Dynamed 
• UptoDate 
• Epocrates 
• Medscape 
• CDC 
• USPSTF 
• SAMHSA Publications 
• ASAM National Practice Guideline 
• Current Medical Diagnosis and Treatment, Lange Series. 
• Primary Practice Guidelines in Primary Care 
• American Academy of Family Physicians.  aafp.org/online   
• National Heart, Lung and Blood Institute Guidelines.  nhlbi.nih.gov/guidelines   
• Procedures for the Primary Care Provider 
• Ferri’s Best Test  
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Appendix O:   Patient Satisfaction Survey 
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Appendix P:  Provider Satisfaction Survey  
 
Survey Monkey  
Provider Satisfaction Survey MAT Group 
1. Question Title 
a) 1. What qualities do you think make a successful 
MAT program? w 
2. Question Title 
a) 2. What qualities or characteristics do you feel have 
made the MAT program at CoRR successful? w 
3. Question Title 
a) 3. What would you like to see improve or change in 
regard to the MAT program at CoRR? w 
4. Question Title 
a) 4. Would you like to see the interdisciplinary MAT 
Group on Tuesday and Wednesday continue at CoRR?  w 
Yes 
No 
Other (please specify) 
DONE 
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Appendix Q: MAT Group Benchmark Data  
 
CoRR MAT Group Pilot Program Data 
Patient ID by DOB Age Range  Patient # Gender  Age  Visits Retention  
Retention 
By Age 
(Headcount) 
Retention 
By Age 
(%) 
August 15, 1997 
18-25 years 
11 F 22 3 1   
September 1, 1996 10 M 23 8 1 2 6% 
September 23, 1992 
26-34 years 
24 F 27 5 1 
  
July 11, 1992 21 F 27 4 1 
May 9, 1992 13 M 27 6 1 
December 31, 1991 29 M 27 4 1 
August 14, 1991 25 M 28 3 1 
July 19, 1991 5 F 28 2 1 
December 11, 1990 1 M 28 2 1 
November 15, 1990 19 M 28 4 1 
September 7, 1990 12 M 29 2 1 
June 27, 1990 6 M 29 7 1 
December 25, 1989 33 F 29 6 1 
July 13, 1989 4 M 30 5 1 
March 10, 1989 34 F 30 5 1 
March 6, 1989 31 M 30 2 1 
November 13, 1988 9 M 30 4 1 
June 16, 1988 3 F 31 2 1 
January 5, 1988 14 M 31 5 1 
April 30, 1987 2 F 32 3 1 
April 30, 1987 35 F 32 2 1 
December 29, 1986 20 F 32 8 1 
April 8, 1986 8 M 33 3 1 21 60% 
August 6, 1984 
35-55 years 
18 F 35 3 1 
  
December 26, 1982 30 M 36 2 1 
January 28, 1982 7 F 37 12 1 
December 10, 1981 16 M 37 5 1 
December 17, 1980 28 M 38 7 1 
February 24, 1979 32 F 40 3 1 
September 15, 1977 17 M 42 5 1 
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January 25, 1977 27 M 42 3 1 
December 28, 1972 15 M 46 4 1 
February 3, 1969 22 M 50 8 1 
November 18, 1963 23 M 55 6 1 11 31% 
December 10, 1949 55 years + 26 M 69 6 1 1 3% 
                  
            TOT 35* 100% 
 
MAT Retention Rate (%) 
N = 47 Total Patients 
R = 35* Repeats (2<) 
Retention Rate 74% 
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Appendix R: Review of the Evidence  
Citation Conceptual  
Framework 
Design/Method Sample/ 
Setting 
Variables  
Studied and 
their Definitions 
Measurement Findings  Appraisal  
Cicero, T.J., Ellis, 
M.S., Surratt, H.L. 
Kurtz, S.P. (2014). 
The changing face of 
heroin use in the 
united states a 
retrospective analysis 
of the past 50 years. 
Journal of American 
Medical Association 
Psychiatry,7(17), 
821-826. doi: 
10.1001/jamapsych 
Iatry.2014.366 
N/A Retrospective 
analysis, 
utilizing a 
mixed-method 
approach  
 -ongoing 
nationwide 
Survey of Key 
Informants’ 
Patients (SKIP) 
Program study 
data employing 
structured, self-
administered 
surveys to 
obtain 
retrospective 
data on prior 
drug use 
patterns for 
patients 
enrolling in 
substance abuse 
treatment 
programs 
across the 
United States 
and who had a 
primary 
diagnosis 
(DSM-IV) of 
heroin 
use/dependence  
 
-IV: patients with 
a primary 
diagnosis (DSM-
IV) of heroin 
use/dependence 
who were 
enrolled in 
substance abuse 
treatment 
programs in the 
United States  
 
-DV: past drug 
use patterns, 
population 
demographics 
and current 
residential 
location 
 -population 
demographics 
and current 
residential 
location 
 
-cross- 
tabulations to 
determine 
prevalence rates 
in terms of the 
decade of when 
the participant 
first abused 
opioids for: 1st 
opioid used (i.e. 
prescription 
opioid or 
heroin), sex, 
race/ethnicity 
and age at first 
use 
-Researchers 
found that the 
demographics of 
heroin users in the 
United States has 
changed from that 
of a minority and 
inner-city 
problem, to one 
that has a larger 
geographic impact 
and is now 
composed of 
mostly white men 
and women (late 
20’s) that reside 
outside large 
urban locations  
 
-The research 
indicated that 
many heroin users 
had previously 
used prescription 
opioids  
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-data collected 
from 
unstructured 
qualitative 
interviews with 
a portion of the 
patients who 
participated in 
the structured 
interview  
Fiellin, D.A., 
Pantalon, M.V., 
Chawarski, M.C., 
Moore, B.A., Sulivan, 
L.E., O’Connor, P.G., 
& Schottenfeld, R.S. 
(2006). Counseling 
plus buprenorphine-
naloxone maintenance 
therapy for opioid 
dependence. The New 
England Journal of 
Medicine, 355, 365-
374. DOI: 10.1056/ 
NEJMoa055255 
N/A 24-week 
randomized, 
controlled 
clinical trial  
166 patients 
who met 
criteria for 
opioid 
dependence and 
for opioid-
agonist 
medication 
treatment and 
were assigned 
to one of three 
treatments: 
-standard 
medical 
management 
 
-either once-
weekly or 
thrice-weekly 
medication 
dispensing 
 
IV: one of three 
treatments--
standard medical 
management, 
either once-
weekly or thrice 
weekly 
medication 
dispensing or 
enhanced 
medical 
management and 
thrice-weekly 
medication 
dispensing 
 
DV: frequency of 
self-reported 
drug use and 
urinalysis testing  
Primary 
outcome 
measures:  
 
-Self reported 
frequency of 
illicit opioid use 
 
-percentage of 
opioid-negative 
urine specimens 
 
-self-reported 
maximum 
number of 
consecutive 
weeks of 
abstinence from 
illicit opioids 
(confirmed 
w/urinalysis)  
 
-All three of the 
treatments in the 
study yielded a 
decrease in the 
mean self-
reported 
frequency of 
opioid use  
 
-No considerable 
difference among 
the three 
treatment groups 
or the treatments 
over time  
 
-Frequency of 
illicit opioid use 
was decreased 
from baseline to 
induction and the 
lowest numbers 
were seen during 
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-enhanced 
medical 
management 
and thrice-
weekly 
medication 
dispensing  
 
Setting: 
Primary Care 
Center of Yale-
New Haven 
Hospital  
Secondary 
outcome 
measures:  
 
-amount of 
patients 
remaining in the 
study  
 
-# of days of the 
study completed 
 
-percentage of 
cocaine-negative 
urine samples 
-patient 
satisfaction 
-use of health 
and social 
services  
 
the maintenance 
phase in all three 
treatment groups  
 
-Strategies to 
improve 
buprenorphine-
naloxone 
adherence 
necessary   
Florence, C., Luo, F., 
Xu, L., & Zhou, C. 
(2016). The economic 
burden of prescription 
opioid overdose, 
abuse and dependence 
in the united states, 
2013. Medical Care, 
54(10), 901-906.  
 
 
 
Societal 
perspective  
-Incidence of 
fatal prescription 
overdose from 
the National Vita 
Statistics System 
 
-Prevalence of 
abuse and 
dependence from 
the National 
Survey of Drug 
Use and Health 
-United States  
population 
(fatal data) 
 
-Representative 
sample of 
United States 
civilian non-
institutionalized 
population ages 
12 and older 
(nonfatal data)  
IV: patients with 
opioid abuse and 
dependence  
 
 
DV:  
-Loss of 
productivity 
defined as job 
status and 
household 
responsibilities  
Monetized strain 
due to fatal 
overdose and 
misuse and 
prescription 
opioid 
dependence  
-The researchers 
estimate that the 
total economic 
burden to equal 
$78.5 billion  
 
-One third of the 
total amount is 
due to the 
increased health 
care costs and cost 
of substance 
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-Cost data from 
health care 
claims data from 
Truven Health 
MarketScan 
Research 
databases 
 
-Cost fatal cases 
from WISQARS 
(Web-based 
injury Statistics 
Query and 
Reporting 
System) cost 
module  
 
-Criminal justice 
costs from the 
Justice 
Expenditure and 
Employment 
Extracts from the 
Department of 
Justice  
 
-Estimates of 
lost productivity 
derived from a 
previously 
published study  
 
-Cost 
components 
which included 
health care, 
substance abuse 
treatment costs, 
criminal justice 
costs and lost 
productivity  
 
-Incidence of 
prescription 
opioid abuse and 
dependence  
abuse treatment 
estimated to be 
$28.9 billion 
 
-One quarter of 
the total cost is 
absorbed by the 
public sector (i.e. 
health care, 
substance abuse 
treatment, 
criminal justice 
costs) 
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Fudala, P.J., Bridge, 
T.P., Herbert, S., 
Williford, W.O., 
Chiang, C.N., Jones, 
K., Collins, J., Raisch, 
D., Casadonte, P., 
Goldsmith, R.J., Ling, 
W., Malkerneker, U., 
McNicholas, L., 
Renner, J., Stine, S., 
& Tusel, D.(2003). 
Office-based 
treatment of opiate 
addiction with a 
sublingual-tablet 
formulation of 
buprenorphine and 
naloxone. New 
England Journal of 
Medicine, 349, 949-
958. DOI: 
10.1056/NEJMoa022 
164 
 
N/A Multicenter, 
randomized, 
placebo-
controlled trial  
-326 patients 
with opioid 
dependence 
(ages 18-59) 
who received 
office-based 
treatment   
 
-Patients either 
received 
buprenorphine 
(16mg) 
w/naloxone 
(4mg), only 
buprenorphine 
(16mg), or a 
placebo daily 
for four weeks   
 
-“Safety data” 
collected on 
461 patients 
w/opioid 
dependence 
who were 
enrolled in an 
open label 
study of 
buprenorphine 
and naloxone 
(daily doses=24 
mg and 6mg) 
and 11 patients 
IV: Patients with 
opioid 
dependence 
receiving office-
based treatment 
w/ either 
buprenorphine 
(16mg) 
w/naloxone 
(4mg), only 
buprenorphine 
(16mg), or a 
placebo daily for 
four weeks   
 
DV: reduction in 
the use of opiates 
and cravings for 
opiates among 
opiate addicted 
patients  
-percentage of 
urine samples (-) 
opiates  
 
-patients self-
reported craving 
for opiates  
-Researchers 
concluded the 
double-blind trial 
prematurely as the 
buprenorphine + 
naloxone 
combination and 
buprenorphine 
were found to be 
more effective 
than the placebo.  
 
-combination 
buprenorphine 
and naloxone and 
buprenorphine 
were found to be 
safe and a decline 
in the use of 
opiates and 
cravings was seen 
in opiate 
dependent patients 
who received 
these medications 
in the office-based 
setting 
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who were given 
this medication 
combination 
during the trial 
only  
Jones, E.B. (2018). 
Medication-Assisted 
opioid treatment 
prescribers federally 
qualified health 
centers: capacity lags 
in rural areas. The 
Journal of Rural 
Health, 34, 14-22. 
doi: 10.1111/ 
jrh.12260 
 
N/A -Descriptive and 
multivariable 
analyses with the 
weighted 2010 
Assessment of 
Behavioral 
Health Services 
survey data and 
the 2010 
Uniform Data 
System  
 
-Stata version 12 
(Stat-aCorp LP, 
College Station, 
Texas) utilized 
to conduct the 
analysis  
-2010 Uniform 
Data System 
(UDS) 
administrative 
data set 
 
-2010 
Assessment of 
Behavioral 
Health Services 
in Federally 
Qualified 
Health Centers  
-Independent 
variables: 
number of 
patients served 
annually, region, 
urban status, 
electronic health 
record adoption, 
whether the 
health center 
received funding 
to serve homeless 
individuals and 
migrant and 
seasonal 
farmworkers, and 
the percentage of 
health center staff 
that were 
behavioral health 
specialists (in the 
models on the 
availability of on-
site 
buprenorphine 
and interest in 
adding or 
expanding the 
-The availability 
of on-site 
treatment for 
substance use 
disorders in 
2010  
 
-The availability 
of on-site mental 
health treatment 
services on-site 
in 2010  
2010 Findings: 
-47.6% of health 
centers provided 
on-site substance 
use disorder 
treatment 
 
-12.3% provided 
buprenorphine 
treatment for 
opioids  
 
-38.8% interested 
in expanding 
buprenorphine 
availability  
 
-Health centers 
located in rural 
areas had 
decreased odds of 
providing on-site 
buprenorphine 
treatment 
(OR=0.49, 95% 
CI: 0.26-0.94) 
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availability of on-
site medication-
assisted treatment 
w/buprenorphine)  
 
-the insurance 
status and type of 
patient caseload 
(uninsured, 
Medicaid, 
Medicare, other 
public and 
private) 
-Rural health 
centers had 
decreased odds of 
showing interest 
in growing access 
to buprenorphine 
treatment (OR- 
0.58, 95% CI: 
0.35-0.97)  
Schwartz, R.P., 
Gryczynski, J., 
O’Grady, K.E., 
Sharfstein, J.M., 
Warren, G., Olsen, 
Y., Mitchell, S.G., & 
Jaffe, J.H. (2013). 
Opioid agonist 
treatments and heroin 
overdose deaths in 
baltimore, maryland, 
1995-2009. American 
Journal of Public 
Health, 103(5), 917-
922. 
doi:[10.2105/AJPH. 
2012.301049] 
N/A Longitudinal 
time series 
analysis of 
archival data 
using linear 
regression with 
the Newey-West 
method  
-The number of 
heroin overdose 
deaths from 
1995-2009 
from the 
Baltimore City 
Health 
Department  
 
-The number of 
patients 
participating in 
Methadone 
treatment for 
opioid 
dependence in 
Baltimore City 
from 1995-
2009 from the 
Maryland 
IV:  
the development 
of opioid agonist 
(i.e. methadone 
and 
buprenorphine) 
treatment  
 
DV: The number 
of heroin 
overdose deaths 
from 1995-2009 
The correlation 
between the 
development of 
methadone and 
buprenorphine 
treatment and 
the incidence of 
heroin overdose 
deaths in 
Baltimore 
Maryland 
between the 
years of 1995-
2009 
-The researchers 
found that 
increased access 
to opioid agonist 
treatment (i.e. 
methadone or 
buprenorphine) 
were correlated 
with a decreased 
number of heroin 
overdose deaths. 
 
-Schwartz et al. 
recommend 
enacting policies 
that are congruent 
with evidence-
based medication 
treatment of 
opiate dependence 
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Department of 
Health’s 
Alcohol and 
Drug 
Administration  
 
-Estimated 
number of 
patients being 
treated with 
buprenorphine-
naloxone 
(Suboxone) or 
buprenorphine 
(Subutex) from 
Wolters Kluwer 
Pharma 
Solutions 
(WKPS) 
as it may lead to a 
reduction in the 
amount of heroin 
overdose deaths  
Tsui, J.I., Evans, J.L., 
Lum, P.J., Hahn, J.A., 
& Page, K. (2014). 
Association of opioid 
agonist therapy with 
lower incidence of 
hepatitis c virus 
infection in young 
adult injection drug 
users. Journal of the 
American Medical 
Association Internal 
Medicine, 174(12), 
N/A Observational 
cohort study 
from 01/03/00-
08/21/13 with 
quarterly 
interviews and 
blood sampling  
Young adults 
age <30 years 
who were 
injection drug 
users and were 
(-) anti-HCV 
antibody and/or 
HCV RNA in 
San Francisco  
IV: opioid 
agonist therapy 
(i.e. 
buprenorphine or 
methadone) 
 
DV: lower 
incidence of 
HCV infection in 
young adult IV 
drug users  
-HCV infection 
documented 
w/new + result 
for HCV RNA 
and/or HCV 
antibodies 
-Researchers 
found that young 
adult participants 
with recent 
maintenance 
opioid agonist 
therapy had an 
associated lower 
rate of HCV 
infection.  
 
-Maintenance 
treatment with 
opioid agonist 
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1974-1981. 
doi:10.1001/ 
jamainternmed.2014. 
5416 
therapy (i.e. 
methadone or 
buprenorphine) 
for opioid use 
disorders may 
help to prevent the 
contraction of 
HCV infection in 
this patient 
population  
Weiss, R.D., Potter, 
J.S., Fiellin, D.A., 
Byrne, M., Connery, 
H.S., Dickinson, W., 
Gardin, J., Griffin, 
M.L., Gourevitch, 
M.N., Haller, D.L. 
Hasson, A.L., Huang, 
Z., Jacobs, P., 
Kosinski, A.S., 
Lindblad, R., 
McCance-Katz, E.F., 
Provost, S.E., Selzer, 
J., Somoza, E.C., 
Sonne, S.C., & Ling, 
W. (2011). 
Adjunctive 
counseling during 
brief and extended 
buprenorphine-
naloxone treatment 
for prescription 
opioid dependence a 
N/A Multi-site 
randomized 
clinical trial 
utilizing a two-
phase adaptive 
treatment 
research design  
 
 
-Study 
participants 
were age 18 or 
older and 
included 653 
treatment-
seeking 
outpatients that 
were dependent 
on prescription 
opioids  
 
-10 treatment 
sites in the 
United States 
that complied 
w/DSM-IV 
criteria for 
prescription 
opioid 
dependence 
from June 
2006-July 2009 
IV: 653 treatment 
seeking 
outpatients 
dependent on 
prescription 
opioids at 10 
U.S. sites  
 
DV: minimal or 
no opioid use at 
phase 1 and/r 
phase 2  
Researchers 
defined 
“successful 
outcome” in 
phases 1 and 2 if 
all determined 
variables 
demonstrated 
minimal or no 
opioid use on 
urine drug 
screen 
confirmed  
patient self-
reports 
-The researchers 
concluded that 
patients with 
prescription 
opioid 
dependence were 
“most likely” to 
decrease opioid 
use during 
buprenorphine-
naloxone 
treatment 
 
-Patients that were 
stabilized on 
buprenorphine-
naloxone had 
improved 
outcomes versus 
those patients who 
were tapered off.  
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2-phase randomized 
controlled trial. 
Archive of General 
Psychiatry, 68(12), 
1238-1246. 
Doi:[10.1001/arch 
genpsychiatry.2011. 
121] 
-Results of the 
study found that if 
patients were 
tapered off 
buprenorphine-
naloxone 
(including  after 
12 wks of 
treatment) there 
was a higher 
possibility for 
unsuccessful 
outcome even if 
patients were 
undergoing 
counseling with 
medical 
management    
Weisner, C., Mertens, 
J., Parthasarathy, S., 
Moore, C., & Lu, Y. 
(2001). Integrating 
primary medical care 
with addiction 
treatment. Journal of 
American Medical 
Association, 286(14), 
1715-1723. Retrieved 
from 
https://www.ncbi.nlm. 
nih.gov/pmc/articles/ 
PMC3056510/ 
N/A Randomized 
controlled trial  
Adult men and 
women (n=592) 
who were 
admitted to a 
large health 
maintenance 
organization 
chemical 
dependency 
program in 
Sacramento, 
CA 
IV: integrated 
care (primary 
health care + 
addiction 
treatment 
program), 
independent care 
groups (separate 
primary care and 
substance abuse 
treatment)  
 
DV: 
-Abstinence 
outcomes 
 
-treatment 
utilization 
 
-6 month costs 
after 
randomization  
Researchers found 
that the patients 
with substance 
abuse-related 
medical 
conditions 
benefited from the 
integrated medical 
and substance 
abuse treatment 
and this method 
was cost 
advantageous  
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Rosenblatt, R.A., 
Andrilla, C.H.A., 
Catlin, M., & Larson, 
E.H. (2015). 
Geographic and 
specialty distribution 
of US physicians 
trained to treat opioid 
use disorder. Annals 
of Family Medicine, 
13(1), 23-26. 
doi:10.1370/afm.1735 
N/A Researchers 
correlated 
physicians that 
were waivered to 
prescribe 
buprenorphine 
on the July 2012 
DEA Drug 
Addiction 
Treatment Act 
(DATA) Waived 
Physician List 
with the 
American 
Medical 
Association 
Physician 
Masterfile to 
identify provider 
age, specialty, 
rural or urban 
status and 
geographical 
location  
Physicians 
authorized to 
prescribe 
buprenorphine 
in the United 
States  
IV: Physicians in 
the United States 
who have 
received a DEA 
DATA waiver to 
prescribe 
buprenorphine-
naloxone to treat 
opioid use 
disorder 
 
DV: Access to 
office-based 
treatment of 
opioid use 
disorder (i.e. 
buprenorphine-
naloxone) 
The amount of 
physicians that 
were waivered 
to prescribe 
buprenorphine 
and 
demographic 
data such as 
provider age, 
specialty, rural 
or urban status 
and 
geographical 
location 
-16% of 
psychiatrists held 
a DEA DATA 
waiver (41.6% of 
all MD’s 
w/waivers) but 
were primarily 
located in urban 
areas 
 
-3% of primary 
care providers had 
received DEA 
DATA waivers 
which comprises 
the biggest group 
of MDs’ in rural 
areas in the U.S.  
 
-Most counties in 
the U.S. did not 
have access to 
physicians’ 
w/waivers to 
prescribe 
buprenorphine-
naloxone 
 
-The authors 
suggest increasing 
access to office-
based treatment of 
opioid disorders 
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especially in rural 
areas in the U.S. 
to address the 
combat the 
increase in opioid 
use disorder and 
unintentional 
overdoses  
 
